<html lang="en" class="pb-page js" data-request-id="94d65b3a97347810-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d65b3a97347810-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/RMGhiRoikNmx9S7feB3fZkMxwyZT92h4_ydMlgB0SCUPjTWMZeeINjYlLhlnoZrNXlWpI_oO__9Nfj0pRBhv0Q=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Evinacumab in Patients with Refractory Hypercholesterolemia | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d65b3a97347810-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.7279740426476128"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="Specialties" content="Cardiology">
<meta name="articleType" content="Original Article">
<meta name="articleCategory" content="Research">
<meta name="topics" content="Lipids|Prevention"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2031049","title":"Evinacumab in Patients with Refractory Hypercholesterolemia","category":"Research","type":"Original Article","topics":"Lipids|Prevention","specialties":"Cardiology","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2020-12-10T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"Specialties\" content\u003d\"Cardiology\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Lipids|Prevention\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2031049","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":{"type":"Quick Take","title":"Evinacumab in Refractory Hypercholesterolemia","doi":"10.1056/NEJMdo005903","issueDate":"2020-12-10T00:00Z","age":"6Months-1990","isFree":"n","topics":"Lipids|Prevention","viewType":"Full","specialties":"Cardiology"}};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d65b3a97347810-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Evinacumab in Patients with Refractory Hypercholesterolemia"><meta name="dc.Creator" content="Robert S. Rosenson"><meta name="dc.Creator" content="Lesley J. Burgess"><meta name="dc.Creator" content="Christoph F. Ebenbichler"><meta name="dc.Creator" content="Seth J. Baum"><meta name="dc.Creator" content="Erik S.G. Stroes"><meta name="dc.Creator" content="Shazia Ali"><meta name="dc.Creator" content="Nagwa Khilla"><meta name="dc.Creator" content="Robert Hamlin"><meta name="dc.Creator" content="Robert Pordy"><meta name="dc.Creator" content="Yuping Dong"><meta name="dc.Creator" content="Vladimir Son"><meta name="dc.Creator" content="Daniel Gaudet"><meta name="dc.Description" content="Patients with refractory hypercholesterolemia, who have high low-density lipoprotein (LDL) cholesterol levels despite treatment with lipid-lowering therapies at maximum tolerated doses, have an inc..."><meta name="Description" content="Patients with refractory hypercholesterolemia, who have high low-density lipoprotein (LDL) cholesterol levels despite treatment with lipid-lowering therapies at maximum tolerated doses, have an inc..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2020-12-10"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2031049"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202012103832408"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="10.1056/NEJMe2032798"><meta name="dc.Relation" content="YXQYoa2031049"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2020 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2031049">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2031049">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2031049">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Evinacumab in Patients with Refractory Hypercholesterolemia | NEJM">
        <meta property="og:title" content="Evinacumab in Patients with Refractory Hypercholesterolemia | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2031049">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/5c7f9b97-f91e-40c3-bff7-98a3125bf75e/nejmoa2031049_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/5c7f9b97-f91e-40c3-bff7-98a3125bf75e/nejmoa2031049_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Patients with refractory hypercholesterolemia, who have high low-density lipoprotein
(LDL) cholesterol levels despite treatment with lipid-lowering therapies at maximum
tolerated doses, have an inc...">
        <meta name="twitter:description" content="Patients with refractory hypercholesterolemia, who have high low-density lipoprotein
(LDL) cholesterol levels despite treatment with lipid-lowering therapies at maximum
tolerated doses, have an inc...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="1394">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa2031049">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2031049">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:doi\:10.1056/nejm_2020.383.issue-24;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;article:article:doi\:10.1056/NEJMoa2031049;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2031049" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2031049" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2031049" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2031049" class="inputDoi"><input type="hidden" value="R.S. Rosenson and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2020;383:2307-2319" class="inputCitation"><input type="hidden" value="11-15-2020" class="inputEPubDate"><input type="hidden" value="December 2020" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Evinacumab in Patients with Refractory Hypercholesterolemia" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d65b3a97347810-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Evinacumab in Patients with Refractory Hypercholesterolemia</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Robert S.</span> <span property="familyName">Rosenson</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Lesley J.</span> <span property="familyName">Burgess</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Christoph F.</span> <span property="familyName">Ebenbichler</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Seth J.</span> <span property="familyName">Baum</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Erik S.G.</span> <span property="familyName">Stroes</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Shazia</span> <span property="familyName">Ali</span>, <span property="honorificSuffix">Pharm.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Nagwa</span> <span property="familyName">Khilla</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Robert</span> <span property="familyName">Hamlin</span>, <span property="honorificSuffix">B.S.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Robert</span> <span property="familyName">Pordy</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Yuping</span> <span property="familyName">Dong</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Vladimir</span> <span property="familyName">Son</span>, <span property="honorificSuffix">Ph.D.</span></span>, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Daniel</span> <span property="familyName">Gaudet</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">November 15, 2020</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2020<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">383</span></span>:<span property="pageStart">2307</span>-<span property="pageEnd">2319</span></div><div class="doi">DOI: 10.1056/NEJMoa2031049</div><div class="core-enumeration"><a href="/toc/nejm/383/24"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">383</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">24</span></span></a></div><div><a href="#tab-information">Copyright © 2020</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DRobert%2BS.%2BRosenson%252C%2BLesley%2BJ.%2BBurgess%252C%2BChristoph%2BF.%2BEbenbichler%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D383%26issueNum%3D24%26contentID%3D10.1056%252FNEJMoa2031049%26title%3DEvinacumab%2Bin%2BPatients%2Bwith%2BRefractory%2BHypercholesterolemia%26publicationDate%3D12%252F10%252F2020" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2031049" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DRobert%2BS.%2BRosenson%252C%2BLesley%2BJ.%2BBurgess%252C%2BChristoph%2BF.%2BEbenbichler%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D383%26issueNum%3D24%26contentID%3D10.1056%252FNEJMoa2031049%26title%3DEvinacumab%2Bin%2BPatients%2Bwith%2BRefractory%2BHypercholesterolemia%26publicationDate%3D12%252F10%252F2020" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/d098fc0a-eb69-4e84-9e0b-223d7b9a5780/nejmoa2031049.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2031049.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2031049" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2031049" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2031049.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Patients with refractory hypercholesterolemia, who have high low-density lipoprotein (LDL) cholesterol levels despite treatment with lipid-lowering therapies at maximum tolerated doses, have an increased risk of atherosclerosis. In such patients, the efficacy and safety of subcutaneous and intravenous evinacumab, a fully human monoclonal antibody against angiopoietin-like 3, are not known.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">In this double-blind, placebo-controlled, phase 2 trial, we enrolled patients with or without heterozygous familial hypercholesterolemia who had refractory hypercholesterolemia, with a screening LDL cholesterol level of 70 mg per deciliter or higher with atherosclerosis or of 100 mg per deciliter or higher without atherosclerosis. Patients were randomly assigned to receive subcutaneous or intravenous evinacumab or placebo. The primary end point was the percent change from baseline in the LDL cholesterol level at week 16 with evinacumab as compared with placebo.</div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">In total, 272 patients were randomly assigned to the following groups: subcutaneous evinacumab at a dose of 450 mg weekly (40 patients), 300 mg weekly (43 patients), or 300 mg every 2 weeks (39 patients) or placebo (41 patients); or intravenous evinacumab at a dose of 15 mg per kilogram of body weight every 4 weeks (39 patients) or 5 mg per kilogram every 4 weeks (36 patients) or placebo (34 patients). At week 16, the differences in the least-squares mean change from baseline in the LDL cholesterol level between the groups assigned to receive subcutaneous evinacumab at a dose of 450 mg weekly, 300 mg weekly, and 300 mg every 2 weeks and the placebo group were −56.0, −52.9, and −38.5 percentage points, respectively (P&lt;0.001 for all comparisons). The differences between the groups assigned to receive intravenous evinacumab at a dose of 15 mg per kilogram and 5 mg per kilogram and the placebo group were −50.5 percentage points (P&lt;0.001) and −24.2 percentage points, respectively. The incidence of serious adverse events during the treatment period ranged from 3 to 16% across trial groups.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">In patients with refractory hypercholesterolemia, the use of evinacumab significantly reduced the LDL cholesterol level, by more than 50% at the maximum dose. (Funded by Regeneron Pharmaceuticals; ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT03175367" target="_blank">NCT03175367</a>.)</div></section></section><div class="core-digital-object quick-take">
<div class="ng-do-media" style="border-top: 1px solid #e5e5e5; padding-top: 1.5rem;" data-location="inlineArticlePreview">
    <div class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="/do/10.1056/NEJMdo005903/full/" class="ng-do-media_item-img-link">
                <img src="/cms/asset/e871a804-6e49-44ea-8549-6b08a98d164d/media/NEJMdo005903_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-video"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/quick-take" class="ng-do-media_item-type-link">Quick Take</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="/do/10.1056/NEJMdo005903/full/" class="ng-do-media_item-title-link">Evinacumab in Refractory Hypercholesterolemia</a>
            </h6>
            <div class="ng-do-media_item-duration">2m 8s</div>
        </div>
    </div>
</div>
</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Lifelong exposure to elevated low-density lipoprotein (LDL) cholesterol levels is associated with an increased risk of atherosclerotic cardiovascular disease.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1" href-manipulated="true" aria-label="Reference 1">1</a></sup> In the United States, approximately 7% of adults receive a diagnosis of severe hypercholesterolemia, defined as having untreated LDL cholesterol levels of 190 mg per deciliter (4.91 mmol per liter) or higher.<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2" id="body-ref-r2-1" href-manipulated="true" aria-label="Reference 2">2</a></sup> In one study, a familial hypercholesterolemia mutation was present in 1.7% of 1386 patients with severe hypercholesterolemia.<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2" id="body-ref-r2-2" href-manipulated="true" aria-label="Reference 2">2</a></sup> In a meta-analysis involving 11 million adults, the worldwide prevalence of familial hypercholesterolemia among those with severe hypercholesterolemia was 7.2%.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3" id="body-ref-r3-1" href-manipulated="true" aria-label="Reference 3">3</a></sup></div><div role="paragraph">Heterozygous familial hypercholesterolemia is an autosomal dominant genetic disorder that is most often caused by mutations in the LDL receptor gene, resulting in decreased or absent hepatic clearance of LDL cholesterol from the circulation and in an elevated plasma LDL cholesterol level.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4 r5 r6" id="body-ref-r6" href-manipulated="true">4-6</a></sup> In the general population, the estimated prevalence of heterozygous familial hypercholesterolemia is 0.32%, which suggests that 1 in 313 people is affected.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3" id="body-ref-r3-2" href-manipulated="true" aria-label="Reference 3">3</a></sup> In the aforementioned meta-analysis, the worldwide prevalence of heterozygous familial hypercholesterolemia among people with atherosclerotic cardiovascular disease, premature atherosclerotic cardiovascular disease, or severe hypercholesterolemia was determined to be 10, 20, and 23 times as high, respectively, as the prevalence in the general population.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3" id="body-ref-r3-3" href-manipulated="true" aria-label="Reference 3">3</a></sup> Data from 1493 patients with heterozygous familial hypercholesterolemia in the Spanish SAFEHEART registry showed that 22.1% had atherosclerotic cardiovascular disease and 10.3% had cardiovascular events during a mean follow-up of 3.9 years.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7" id="body-ref-r7" href-manipulated="true" aria-label="Reference 7">7</a></sup> As compared with the risk of coronary artery disease in a reference group of patients with LDL cholesterol levels of less than 130 mg per deciliter (3.36 mmol per liter) and no familial hypercholesterolemia mutation, the risk was 6.0 times as high among patients with LDL cholesterol levels of 190 mg per deciliter or higher and no mutation and was 22.3 times as high among patients with LDL cholesterol levels of 190 mg per deciliter or higher and a mutation, findings that reflect the detrimental effect of lifelong exposure to elevated LDL cholesterol levels.<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2" id="body-ref-r2-3" href-manipulated="true" aria-label="Reference 2">2</a></sup> Familial hypercholesterolemia mutations are associated with an increase in the odds of early-onset (≤55 years of age) myocardial infarction by a factor of 3.8.<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8" id="body-ref-r8" href-manipulated="true" aria-label="Reference 8">8</a></sup></div><div role="paragraph">The 2019 European Society of Cardiology (ESC)–European Atherosclerosis Society (EAS) clinical guidelines recommend target LDL cholesterol levels of less than 55 mg per deciliter (1.42 mmol per liter), less than 70 mg per deciliter (1.81 mmol per liter), and less than 100 mg per deciliter (2.59 mmol per liter) in patients with very high, high, and moderate risk for atherosclerotic cardiovascular disease, respectively.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9" id="body-ref-r9-1" href-manipulated="true" aria-label="Reference 9">9</a></sup> The 2018 American College of Cardiology (ACC)–American Heart Association (AHA) guidelines recommend that clinicians use an LDL cholesterol threshold of 70 mg per deciliter or higher to prompt intensification of lipid-lowering therapies in patients with very high risk for atherosclerotic cardiovascular disease.<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="body-ref-r10-1" href-manipulated="true" aria-label="Reference 10">10</a></sup> These treatment goals are difficult to achieve in some patients with heterozygous familial hypercholesterolemia despite treatment with a statin at a maximum tolerated dose, ezetimibe, and a proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor. Although additional lowering of the LDL cholesterol level may be done with LDL apheresis, the use of this invasive approach is restricted by limited accessibility to apheresis centers, high procedural costs, inconvenience to patients, the lack of insurance coverage support, and adverse events.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4 r11 r12" id="body-ref-r12" href-manipulated="true">4,11,12</a></sup></div><div role="paragraph">Angiopoietin-like 3 (ANGPTL3) plays a prominent role in the regulation of lipid metabolism by inhibiting lipoprotein lipase and endothelial lipase.<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13 r14 r15 r16 r17" id="body-ref-r17" href-manipulated="true">13-17</a></sup> Patients with loss-of-function variants of <i>ANGPTL3</i> have a hypolipidemic phenotype, with substantially reduced levels of LDL cholesterol, triglycerides, and high-density lipoprotein (HDL) cholesterol.<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18" id="body-ref-r18-1" href-manipulated="true" aria-label="Reference 18">18</a></sup> Moreover, the risk of coronary artery disease among patients with <i>ANGPTL3</i> loss-of-function variants is 41% lower than the risk in the general population.<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18" id="body-ref-r18-2" href-manipulated="true" aria-label="Reference 18">18</a></sup> Functional analyses conducted in a phase 2 proof-of-concept study suggest that evinacumab, a fully human monoclonal antibody against ANGPTL3, is effective in lowering the LDL cholesterol level with a mechanism independent of the LDL receptor.<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19 r20 r21" id="body-ref-r21-1" href-manipulated="true">19-21</a></sup> In the phase 3 Evinacumab Lipid Studies in Patients with Homozygous Familial Hypercholesterolemia (ELIPSE HoFH), involving 65 patients with homozygous familial hypercholesterolemia, patients who received treatment with evinacumab had a 47.1% reduction from baseline in the LDL cholesterol level at week 24, whereas those who received placebo had a 1.9% increase, resulting in a between-group least-squares mean difference of –49.0 percentage points (P&lt;0.001); results were similar even among those with null variants of homozygous familial hypercholesterolemia (&lt;2% LDL receptor activity).<sup><a href="#core-r22" role="doc-biblioref" data-xml-rid="r22" id="body-ref-r22-1" href-manipulated="true" aria-label="Reference 22">22</a></sup></div><div role="paragraph">In the phase 2 proof-of-concept study and the phase 3 ELIPSE HoFH trial, evinacumab was infused intravenously, over a period of 60 minutes, at a dose of 15 mg per kilogram of body weight every 4 weeks. However, subcutaneous administration of evinacumab can be more convenient for patients. In this trial, we assessed the efficacy and safety of subcutaneous and intravenous evinacumab, as compared with placebo, in patients with refractory hypercholesterolemia who had been treated with maximum tolerated doses of statins and other lipid-lowering therapies, including a PCSK9 inhibitor.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Trial Oversight</h3><div role="paragraph">This randomized, double-blind, placebo-controlled, phase 2 trial was conducted at 85 sites across 20 countries. The trial <a href="#ap1">protocol</a>, available with the full text of this article at NEJM.org, was approved by the institutional review board or ethics committee at each participating site. The trial was conducted in accordance with ethical principles originating from the Declaration of Helsinki and was consistent with International Conference on Harmonisation Good Clinical Practice guidelines and applicable regulatory requirements. The principal investigators and sponsor (Regeneron Pharmaceuticals) designed the trial protocol and selected the participating sites. Clinical trial monitoring and site supervision were performed by a contract research organization with oversight by the sponsor. The sponsor was also involved in the collection, analysis, and interpretation of the data and checked the information provided in the manuscript. The first author wrote the first draft of the manuscript. All the authors had unrestricted access to the trial data, contributed to the first draft of the manuscript, participated in revisions, and vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol. Editorial support for the writing of the manuscript was provided by Prime Global and paid for by the sponsor.</div></section><section id="sec-1-2"><h3>Trial Design and Patients</h3><div role="paragraph">The trial included a run-in period of variable duration for patients who were not receiving a PCSK9 inhibitor or background lipid-lowering therapy at a maximum tolerated dose on a regular basis. The run-in period was followed by a 2-week screening period, a double-blind treatment period lasting 16 weeks for subcutaneous treatment and 24 weeks for intravenous treatment, a 48-week open-label treatment period for intravenous treatment only, and a 24-week follow-up period after the last dose of the trial drug (Fig. S1 in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org).</div><div role="paragraph">Patients 18 to 80 years of age were eligible for inclusion in the trial if they had primary hypercholesterolemia, defined as either heterozygous familial hypercholesterolemia or non–heterozygous familial hypercholesterolemia with clinical atherosclerotic cardiovascular disease. The hypercholesterolemia was refractory to treatment with a PCSK9 inhibitor and a statin at a maximum tolerated dose, with or without ezetimibe. A diagnosis of heterozygous familial hypercholesterolemia was based on genotyping or clinical criteria. For patients who did not undergo genotyping, the clinical diagnosis was based on the Simon Broome criteria for definite familial hypercholesterolemia or the World Health Organization–Dutch Lipid Clinic Network criteria, with a score of more than 8 points (range of possible scores, 0 to 32) indicating a certain diagnosis of heterozygous familial hypercholesterolemia (see the <a href="#ap2">Supplementary Appendix</a>). Refractory hypercholesterolemia was defined as an LDL cholesterol level of 70 mg per deciliter or higher with clinical atherosclerotic cardiovascular disease or a level of 100 mg per deciliter or higher without clinical atherosclerotic cardiovascular disease. The full list of eligibility criteria is provided in the <a href="#ap2">Supplementary Appendix</a>. Written informed consent was obtained from each patient in the trial.</div></section><section id="sec-1-3"><h3>Randomization</h3><div role="paragraph">Patients were randomly assigned to receive subcutaneous treatment (one of three evinacumab regimens or placebo, assigned in a 1:1:1:1 ratio) or intravenous treatment (one of two evinacumab regimens or placebo, assigned in a 1:1:1 ratio). Randomization was stratified according to the presence or absence of heterozygous familial hypercholesterolemia (2:1 ratio) and to the receipt or nonreceipt of a high-intensity statin. The subcutaneous regimens were evinacumab at a dose of 450 mg weekly, 300 mg weekly, or 300 mg every 2 weeks or placebo weekly. The intravenous regimens were evinacumab at a dose of 15 mg per kilogram of body weight every 4 weeks or 5 mg per kilogram every 4 weeks or placebo every 4 weeks. All patients who were assigned to the intravenous-treatment groups entered the 48-week open-label treatment period, in which they received intravenous evinacumab at a dose of 15 mg per kilogram every 4 weeks, regardless of their treatment assignment in the double-blind treatment period. In this article, we present the results from the double-blind treatment period.</div></section><section id="sec-1-4"><h3>End Points</h3><div role="paragraph">The primary end point was the percent change from baseline in the LDL cholesterol level at week 16 with subcutaneous or intravenous evinacumab as compared with placebo. The LDL cholesterol level was calculated with the use of the Friedewald formula.<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23" id="body-ref-r23" href-manipulated="true" aria-label="Reference 23">23</a></sup> Secondary end points included lipid levels. Safety was evaluated on the basis of the incidence of adverse events that occurred during the double-blind treatment period. Lists of secondary end points and protocol-defined adverse events of special interest are provided in the <a href="#ap2">Supplementary Appendix</a>.</div></section><section id="sec-1-5"><h3>Statistical Analysis</h3><div role="paragraph">We calculated that a sample of 36 patients per trial group would provide the trial with 90% power to detect a between-group difference in the mean percent change in the LDL cholesterol level of 20 percentage points in any one pairwise comparison with the use of an independent group t-test with a 0.05 two-sided significance level, under the assumption of a common standard deviation of 25%, with adjustment to account for a 5% dropout rate. The primary efficacy end point of the percent change from baseline in the calculated LDL cholesterol level at week 16 during the double-blind treatment period was analyzed in the intention-to-treat population with the use of a mixed-effect model with a repeated-measures approach. The model included the categorical fixed effects of treatment (evinacumab or placebo), randomization strata (receipt of a high-intensity statin [yes or no] and presence of heterozygous familial hypercholesterolemia [yes or no]), time point up to week 16, strata-by-time point interaction, and treatment-by-time point interaction, as well as the continuous fixed covariates of the calculated LDL cholesterol level at baseline and baseline LDL cholesterol level-by-time point interaction. The model provided baseline-adjusted least-squares mean estimates at week 16 with corresponding 95% confidence intervals and standard errors.</div><div role="paragraph">Four between-group comparisons were performed with regard to the primary end point: intravenous evinacumab at a dose of 15 mg per kilogram every 4 weeks was compared with intravenous placebo, and each of the three doses of subcutaneous evinacumab (450 mg weekly, 300 mg weekly, and 300 mg every 2 weeks) was compared with subcutaneous placebo. The statistical testing of these four pairwise comparisons with regard to the primary end point was performed with the use of a hierarchical inferential approach to adjust for multiplicity; testing was to be performed in the order shown above, with each subsequent test performed when the primary end-point results were significant at an alpha level of 0.05. The regimen of intravenous evinacumab at a dose of 5 mg per kilogram every 4 weeks was added to allow for an initial assessment of the dose–response relationship with the intravenous route of administration. Secondary efficacy end points and the comparison of intravenous evinacumab at a dose of 5 mg per kilogram with placebo were assessed descriptively. Baseline and safety data were assessed with the use of descriptive statistics. The statistical analysis plan did not include a provision for correction for multiplicity in tests for secondary or other outcomes; results for these outcomes are reported as point estimates and 95% confidence intervals. Because the widths of the confidence intervals have not been adjusted for multiplicity, they should not be used to infer definitive treatment effects with regard to secondary outcomes.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Trial Groups</h3><div role="paragraph">Overall, 272 patients were randomly assigned to receive subcutaneous evinacumab or placebo (163 patients) or intravenous evinacumab or placebo (109 patients) (Fig. S2). The subcutaneous regimens were evinacumab at a dose of 450 mg weekly (40 patients), 300 mg weekly (43 patients), or 300 mg every 2 weeks (39 patients) or placebo weekly (41 patients). The intravenous regimens were evinacumab at a dose of 15 mg per kilogram every 4 weeks (39 patients) or 5 mg per kilogram every 4 weeks (36 patients) or placebo every 4 weeks (34 patients). Six patients (3 assigned to a subcutaneous regimen and 3 assigned to an intravenous regimen) did not receive the trial agent. Thus, the intention-to-treat population included 266 patients (160 assigned to a subcutaneous regimen and 106 assigned to an intravenous regimen).</div></section><section id="sec-2-2"><h3>Patient Characteristics</h3><section id="sec-2-2-1"><h4>Subcutaneous Evinacumab</h4><div role="paragraph">The demographic and clinical characteristics of the patients at baseline were generally well balanced among the subcutaneous-treatment groups (<a href="#t1">Table 1</a>). In total, 116 patients (72%) had heterozygous familial hypercholesterolemia and 44 (28%) did not. The baseline mean (±SD) LDL cholesterol level was similar among patients assigned to receive evinacumab at a dose of 450 mg weekly (146.3±84.6 mg per deciliter [3.78±2.19 mmol per liter]), evinacumab at a dose of 300 mg weekly (159.1±73.0 mg per deciliter [4.11±1.89 mmol per liter]), and placebo (157.8±92.4 mg per deciliter [4.08±2.39 mmol per liter]) but was lower among patients assigned to receive evinacumab at a dose of 300 mg every 2 weeks (136.2±70.2 mg per deciliter [3.52±1.82 mmol per liter]). All the patients were receiving a PCSK9 inhibitor, 44% were receiving a high-intensity statin (with all these patients receiving a maximum tolerated dose of the statin), and 30% were receiving ezetimibe.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2031049_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2031049_t1.jpg"><img src="/cms/10.1056/NEJMoa2031049/asset/9fbcb9ec-73d2-4bd8-a8f5-f92bd765de62/assets/images/large/nejmoa2031049_t1.jpg" height="3081" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders" colspan="3"><span>Subcutaneous Evinacumab</span></th><th class="txxx-borders">Subcutaneous Placebo, Weekly (N=39)</th><th class="txxr-borders">Total (N=160)</th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">450 mg Weekly (N=40)</th><th class="xxxx-borders">300 mg Weekly (N=42)</th><th class="xxxx-borders">300 mg Every 2 Wk (N=39)</th><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Age — yr</td><td class="xxxx-borders shading">54.5±15.1</td><td class="xxxx-borders shading">54.0±12.2</td><td class="xxxx-borders shading">55.0±13.0</td><td class="xxxx-borders shading">52.4±12.7</td><td class="xxxr-borders shading">54.0±13.2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders">29 (72)</td><td class="xxxx-borders">23 (55)</td><td class="xxxx-borders">21 (54)</td><td class="xxxx-borders">27 (69)</td><td class="xxxr-borders">100 (62)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Race — no. (%)<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">White</td><td class="xxxx-borders">38 (95)</td><td class="xxxx-borders">39 (93)</td><td class="xxxx-borders">34 (87)</td><td class="xxxx-borders">34 (87)</td><td class="xxxr-borders">145 (91)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Black</td><td class="xxxx-borders shading">1 (2)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">3 (8)</td><td class="xxxr-borders shading">4 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Asian</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">1 (3)</td><td class="xxxr-borders">3 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Other</td><td class="xxxx-borders shading">1 (2)</td><td class="xxxx-borders shading">1 (2)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxr-borders shading">3 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Not reported</td><td class="xxxx-borders">0</td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">3 (8)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">5 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Body-mass index<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">27.9±4.4</td><td class="xxxx-borders shading">29.3±4.9</td><td class="xxxx-borders shading">28.0±4.4</td><td class="xxxx-borders shading">29.1±5.2</td><td class="xxxr-borders shading">28.6±4.7</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Heterozygous familial hypercholesterolemia status — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Present</td><td class="xxxx-borders shading">29 (72)</td><td class="xxxx-borders shading">30 (71)</td><td class="xxxx-borders shading">29 (74)</td><td class="xxxx-borders shading">28 (72)</td><td class="xxxr-borders shading">116 (72)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Diagnosed with genotyping</td><td class="xxxx-borders">13 (32)</td><td class="xxxx-borders">16 (38)</td><td class="xxxx-borders">11 (28)</td><td class="xxxx-borders">9 (23)</td><td class="xxxr-borders">49 (31)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Diagnosed with clinical criteria</td><td class="xxxx-borders shading">16 (40)</td><td class="xxxx-borders shading">14 (33)</td><td class="xxxx-borders shading">18 (46)</td><td class="xxxx-borders shading">19 (49)</td><td class="xxxr-borders shading">67 (42)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Absent</td><td class="xxxx-borders">11 (28)</td><td class="xxxx-borders">12 (29)</td><td class="xxxx-borders">10 (26)</td><td class="xxxx-borders">11 (28)</td><td class="xxxr-borders">44 (28)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Calculated LDL cholesterol — mg/dl</td><td class="xxxx-borders shading">146.3±84.6</td><td class="xxxx-borders shading">159.1±73.0</td><td class="xxxx-borders shading">136.2±70.2</td><td class="xxxx-borders shading">157.8±92.4</td><td class="xxxr-borders shading">150.0±80.2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Apolipoprotein B — mg/dl</td><td class="xxxx-borders">112.4±43.1</td><td class="xxxx-borders">123.2±42.1</td><td class="xxxx-borders">107.8±43.8</td><td class="xxxx-borders">120.6±51.1</td><td class="xxxr-borders">116.1±45.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">HDL cholesterol — mg/dl</td><td class="xxxx-borders shading">52.5±13.8</td><td class="xxxx-borders shading">57.0±22.9</td><td class="xxxx-borders shading">51.7±15.5</td><td class="xxxx-borders shading">56.2±16.7</td><td class="xxxr-borders shading">54.4±17.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Non-HDL cholesterol — mg/dl</td><td class="xxxx-borders">173.0±84.8</td><td class="xxxx-borders">185.1±74.8</td><td class="xxxx-borders">165.3±71.2</td><td class="xxxx-borders">183.9±92.8</td><td class="xxxr-borders">176.9±80.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Total cholesterol — mg/dl</td><td class="xxxx-borders shading">225.5±86.2</td><td class="xxxx-borders shading">242.2±77.3</td><td class="xxxx-borders shading">217.0±68.8</td><td class="xxxx-borders shading">240.1±91.9</td><td class="xxxr-borders shading">231.4±81.4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Median fasting triglycerides (IQR) — mg/dl</td><td class="xxxx-borders">109.5 (82.0–183.5)</td><td class="xxxx-borders">118.5 (83.0–177.0)</td><td class="xxxx-borders">128.0 (87.0–167.0)</td><td class="xxxx-borders">112.0 (85.0–176.0)</td><td class="xxxr-borders">114.5 (85.5–176.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Median lipoprotein(a) (IQR) — nmol/liter</td><td class="xxxx-borders shading">24.5 (15.5–97.5)</td><td class="xxxx-borders shading">81.5 (21.0–231.0)</td><td class="xxxx-borders shading">60.0 (16.0–128.0)</td><td class="xxxx-borders shading">48.0 (21.0–170.0)</td><td class="xxxr-borders shading">46.5 (17.0–154.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Coronary heart disease — no. (%)</td><td class="xxxx-borders">22 (55)</td><td class="xxxx-borders">21 (50)</td><td class="xxxx-borders">22 (56)</td><td class="xxxx-borders">21 (54)</td><td class="xxxr-borders">86 (54)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Acute myocardial infarction</td><td class="xxxx-borders shading">7 (18)</td><td class="xxxx-borders shading">13 (31)</td><td class="xxxx-borders shading">9 (23)</td><td class="xxxx-borders shading">9 (23)</td><td class="xxxr-borders shading">38 (24)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Silent myocardial infarction</td><td class="xxxx-borders">1 (2)</td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">3 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Chronic stable or unstable angina</td><td class="xxxx-borders shading">14 (35)</td><td class="xxxx-borders shading">9 (21)</td><td class="xxxx-borders shading">16 (41)</td><td class="xxxx-borders shading">16 (41)</td><td class="xxxr-borders shading">55 (34)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Coronary revascularization procedure</td><td class="xxxx-borders">17 (42)</td><td class="xxxx-borders">18 (43)</td><td class="xxxx-borders">17 (44)</td><td class="xxxx-borders">13 (33)</td><td class="xxxr-borders">65 (41)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Risk equivalents of coronary heart disease — no. (%)</td><td class="xxxx-borders shading">9 (22)</td><td class="xxxx-borders shading">7 (17)</td><td class="xxxx-borders shading">8 (20)</td><td class="xxxx-borders shading">7 (18)</td><td class="xxxr-borders shading">31 (19)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Peripheral arterial disease</td><td class="xxxx-borders">4 (10)</td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">7 (18)</td><td class="xxxx-borders">4 (10)</td><td class="xxxr-borders">17 (11)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Ischemic stroke</td><td class="xxxx-borders shading">5 (12)</td><td class="xxxx-borders shading">2 (5)</td><td class="xxxx-borders shading">2 (5)</td><td class="xxxx-borders shading">2 (5)</td><td class="xxxr-borders shading">11 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Chronic kidney disease</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (3)</td><td class="xxxr-borders">1 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Known history of type 1 or 2 diabetes mellitus and ≥2 additional risk factors<a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">3 (8)</td><td class="xxxx-borders shading">3 (7)</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxr-borders shading">8 (5)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Lipid-lowering therapy — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Any statin</td><td class="xxxx-borders shading">24 (60)</td><td class="xxxx-borders shading">24 (57)</td><td class="xxxx-borders shading">24 (62)</td><td class="xxxx-borders shading">27 (69)</td><td class="xxxr-borders shading">99 (62)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">High-intensity statin<a href="#t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">17 (42)</td><td class="xxxx-borders">21 (50)</td><td class="xxxx-borders">14 (36)</td><td class="xxxx-borders">19 (49)</td><td class="xxxr-borders">71 (44)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Ezetimibe</td><td class="xxxx-borders shading">7 (18)</td><td class="xxxx-borders shading">15 (36)</td><td class="xxxx-borders shading">12 (31)</td><td class="xxxx-borders shading">14 (36)</td><td class="xxxr-borders shading">48 (30)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging13" data-xml-align="left">PCSK9 inhibitor</td><td class="xbxx-borders">40 (100)</td><td class="xbxx-borders">42 (100)</td><td class="xbxx-borders">39 (100)</td><td class="xbxx-borders">39 (100)</td><td class="xbxr-borders">160 (100)</td></tr></tbody></table></div><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients in the Subcutaneous-Treatment Groups.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Plus–minus values are means ±SD. Data are shown for the intention-to-treat population. Percentages may not total 100 because of rounding. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. To convert the values for triglycerides to millimoles per liter, multiply by 0.01129. HDL denotes high-density lipoprotein, IQR interquartile range, LDL low-density lipoprotein, and PCSK9 proprotein convertase subtilisin–kexin type 9.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">Race was reported by the patient.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">The body-mass index is the weight in kilograms divided by the square of the height in meters.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t1fn4" role="paragraph">Risk factors include a history of an ankle–brachial index of 0.9 or lower, a history of hypertension, a history of microalbuminuria or macroalbuminuria, a history of proliferative diabetic retinopathy, and a known family history of coronary heart disease.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t1fn5" role="paragraph">High-intensity statin was defined as rosuvastatin at a dose of 20 mg or 40 mg daily, atorvastatin at a dose of 40 mg or 80 mg daily, or simvastatin at a dose of 80 mg daily (if the patient had been receiving this regimen for &gt;1 year).</div></div></div></figcaption></figure></div></section><section id="sec-2-2-2"><h4>Intravenous Evinacumab</h4><div role="paragraph">The demographic and clinical characteristics of the patients at baseline were also generally well balanced among the intravenous-treatment groups (<a href="#t2">Table 2</a>). In total, 86 patients (81%) had heterozygous familial hypercholesterolemia and 20 (19%) did not. The baseline mean LDL cholesterol level was similar among patients assigned to receive evinacumab at a dose of 15 mg per kilogram (143.1±54.4 mg per deciliter [3.70±1.41 mmol per liter]), evinacumab at a dose of 5 mg per kilogram (146.0±61.0 mg per deciliter [3.78±1.58 mmol per liter]), and placebo (144.5±46.6 mg per deciliter [3.74±1.21 mmol per liter]). Most of the patients (96%) were receiving a PCSK9 inhibitor, 49% were receiving a high-intensity statin (with all these patients receiving a maximum tolerated dose of the statin), and 38% were receiving ezetimibe.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2031049_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2031049_t2.jpg"><img src="/cms/10.1056/NEJMoa2031049/asset/2884dab0-ac0d-47a3-9162-69ce39e956a5/assets/images/large/nejmoa2031049_t2.jpg" height="2859" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders" colspan="2"><span>Intravenous Evinacumab</span></th><th class="txxx-borders">Intravenous Placebo, Every 4 Wk<br>(N=33)</th><th class="txxr-borders">Total <br>(N=106)</th></tr></thead><tbody><tr class="head2" data-xml-align="center" data-type="row head2" data-xml-valign="bottom"><td class="xxlx-borders hanging03">&nbsp;</td><td class="xxxx-borders">15 mg/kg Every 4 Wk<br>(N=38)</td><td class="xxxx-borders">5 mg/kg Every 4 Wk<br>(N=35)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Age — yr</td><td class="xxxx-borders shading">52.1±12.1</td><td class="xxxx-borders shading">55.7±9.6</td><td class="xxxx-borders shading">56.2±10.9</td><td class="xxxr-borders shading">54.6±11.0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders">19 (50)</td><td class="xxxx-borders">22 (63)</td><td class="xxxx-borders">18 (55)</td><td class="xxxr-borders">59 (56)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Race — no. (%)<a href="#t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">White</td><td class="xxxx-borders">35 (92)</td><td class="xxxx-borders">32 (91)</td><td class="xxxx-borders">27 (82)</td><td class="xxxr-borders">94 (89)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Black</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (6)</td><td class="xxxr-borders shading">2 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Asian</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">1 (3)</td><td class="xxxr-borders">2 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Other</td><td class="xxxx-borders shading">3 (8)</td><td class="xxxx-borders shading">2 (6)</td><td class="xxxx-borders shading">3 (9)</td><td class="xxxr-borders shading">8 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Body-mass index<a href="#t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">29.3±4.9</td><td class="xxxx-borders">28.8±4.6</td><td class="xxxx-borders">28.8±5.2</td><td class="xxxr-borders">29.0±4.9</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Heterozygous familial hypercholesterolemia status — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Present</td><td class="xxxx-borders">31 (82)</td><td class="xxxx-borders">29 (83)</td><td class="xxxx-borders">26 (79)</td><td class="xxxr-borders">86 (81)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Diagnosed with genotyping</td><td class="xxxx-borders shading">10 (26)</td><td class="xxxx-borders shading">11 (31)</td><td class="xxxx-borders shading">11 (33)</td><td class="xxxr-borders shading">32 (30)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Diagnosed with clinical criteria</td><td class="xxxx-borders">21 (55)</td><td class="xxxx-borders">18 (51)</td><td class="xxxx-borders">15 (45)</td><td class="xxxr-borders">54 (51)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Absent</td><td class="xxxx-borders shading">7 (18)</td><td class="xxxx-borders shading">6 (17)</td><td class="xxxx-borders shading">7 (21)</td><td class="xxxr-borders shading">20 (19)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Calculated LDL cholesterol — mg/dl</td><td class="xxxx-borders">143.1±54.4</td><td class="xxxx-borders">146.0±61.0</td><td class="xxxx-borders">144.5±46.6</td><td class="xxxr-borders">144.5±54.0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Apolipoprotein B — mg/dl</td><td class="xxxx-borders shading">112.6±32.4</td><td class="xxxx-borders shading">113.4±33.8</td><td class="xxxx-borders shading">116.7±27.0</td><td class="xxxr-borders shading">114.1±31.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">HDL cholesterol — mg/dl</td><td class="xxxx-borders">51.5±17.4</td><td class="xxxx-borders">58.2±16.8</td><td class="xxxx-borders">55.4±18.0</td><td class="xxxr-borders">54.9±17.4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Non-HDL cholesterol — mg/dl</td><td class="xxxx-borders shading">169.4±54.2</td><td class="xxxx-borders shading">170.6±61.5</td><td class="xxxx-borders shading">176.2±48.0</td><td class="xxxr-borders shading">171.9±54.5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Total cholesterol — mg/dl</td><td class="xxxx-borders">220.9±56.8</td><td class="xxxx-borders">228.8±60.2</td><td class="xxxx-borders">231.6±50.4</td><td class="xxxr-borders">226.8±55.7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Median fasting triglycerides (IQR) — mg/dl</td><td class="xxxx-borders shading">126.5 (89.0–166.0)</td><td class="xxxx-borders shading">102.0 (86.0–156.0)</td><td class="xxxx-borders shading">147.0 (104.0–200.0)</td><td class="xxxr-borders shading">122.0 (92.0–171.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Median lipoprotein(a) (IQR) — nmol/liter</td><td class="xxxx-borders">34.0 (15.0–157.0)</td><td class="xxxx-borders">27.0 (18.0–80.0)</td><td class="xxxx-borders">33.0 (16.0–154.0)</td><td class="xxxr-borders">31.0 (17.0–127.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Coronary heart disease — no. (%)</td><td class="xxxx-borders shading">21 (55)</td><td class="xxxx-borders shading">20 (57)</td><td class="xxxx-borders shading">25 (76)</td><td class="xxxr-borders shading">66 (62)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Acute myocardial infarction</td><td class="xxxx-borders">13 (34)</td><td class="xxxx-borders">10 (29)</td><td class="xxxx-borders">14 (42)</td><td class="xxxr-borders">37 (35)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Silent myocardial infarction</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Chronic stable or unstable angina</td><td class="xxxx-borders">13 (34)</td><td class="xxxx-borders">16 (46)</td><td class="xxxx-borders">16 (48)</td><td class="xxxr-borders">45 (42)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Coronary revascularization procedure</td><td class="xxxx-borders shading">19 (50)</td><td class="xxxx-borders shading">15 (43)</td><td class="xxxx-borders shading">20 (61)</td><td class="xxxr-borders shading">54 (51)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Risk equivalents of coronary heart disease — no. (%)</td><td class="xxxx-borders">10 (26)</td><td class="xxxx-borders">4 (11)</td><td class="xxxx-borders">7 (21)</td><td class="xxxr-borders">21 (20)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Peripheral arterial disease</td><td class="xxxx-borders shading">8 (21)</td><td class="xxxx-borders shading">2 (6)</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxr-borders shading">11 (10)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Ischemic stroke</td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">2 (6)</td><td class="xxxr-borders">5 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Chronic kidney disease</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxr-borders shading">1 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Known history of type 1 or 2 diabetes mellitus and ≥2 additional risk factors<a href="#t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">2 (6)</td><td class="xxxx-borders">4 (12)</td><td class="xxxr-borders">8 (8)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Lipid-lowering therapy — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Any statin</td><td class="xxxx-borders">33 (87)</td><td class="xxxx-borders">27 (77)</td><td class="xxxx-borders">28 (85)</td><td class="xxxr-borders">88 (83)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">High-intensity statin<a href="#t2fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">23 (61)</td><td class="xxxx-borders shading">17 (49)</td><td class="xxxx-borders shading">15 (45)</td><td class="xxxr-borders shading">55 (52)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Ezetimibe</td><td class="xxxx-borders">13 (34)</td><td class="xxxx-borders">15 (43)</td><td class="xxxx-borders">12 (36)</td><td class="xxxr-borders">40 (38)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging13 shading" data-xml-align="left">PCSK9 inhibitor</td><td class="xbxx-borders shading">37 (97)</td><td class="xbxx-borders shading">33 (94)</td><td class="xbxx-borders shading">32 (97)</td><td class="xbxr-borders shading">102 (96)</td></tr></tbody></table></div><figcaption><div class="caption">Demographics and Clinical Characteristics of the Patients in the Intravenous-Treatment Groups.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">Plus–minus values are means ±SD. Data are shown for the intention-to-treat population. Percentages may not total 100 because of rounding. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. To convert the values for triglycerides to millimoles per liter, multiply by 0.01129.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">Race was reported by the patient.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t2fn3" role="paragraph">The body-mass index is the weight in kilograms divided by the square of the height in meters.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t2fn4" role="paragraph">Risk factors include a history of an ankle–brachial index of 0.9 or lower, a history of hypertension, a history of microalbuminuria or macroalbuminuria, a history of proliferative diabetic retinopathy, and a known family history of coronary heart disease.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t2fn5" role="paragraph">High-intensity statin was defined as rosuvastatin at a dose of 20 mg or 40 mg daily, atorvastatin at a dose of 40 mg or 80 mg daily, or simvastatin at a dose of 80 mg daily (if the patient had been receiving this regimen for &gt;1 year).</div></div></div></figcaption></figure></div></section></section><section id="sec-2-3"><h3>Primary Efficacy Analysis</h3><section id="sec-2-3-1"><h4>Subcutaneous Evinacumab</h4><div role="paragraph">At week 16, the change from baseline in the LDL cholesterol level was −47.2% with subcutaneous evinacumab at a dose of 450 mg weekly and −44.0% with subcutaneous evinacumab at a dose of 300 mg weekly, as compared with 8.8% with placebo, with a least-squares mean difference (each of these evinacumab regimens vs. placebo) of –56.0 and −52.9 percentage points, respectively (P&lt;0.001 for both comparisons) (<a href="#f1">Figure 1</a> and <a href="#t3">Table 3</a>). A smaller reduction from baseline in the LDL cholesterol level at week 16 was observed with subcutaneous evinacumab at a dose of 300 mg every 2 weeks, with a least-squares mean difference (vs. placebo) of −38.5 percentage points (P&lt;0.001) (<a href="#f1">Figure 1</a> and <a href="#t3">Table 3</a>). The reduction in the LDL cholesterol level with all three subcutaneous-evinacumab regimens was observed as early as the first postbaseline lipid assessment (week 2) and was maintained through week 16.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2031049_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2031049_f1.jpg"><img src="/cms/10.1056/NEJMoa2031049/asset/5c7f9b97-f91e-40c3-bff7-98a3125bf75e/assets/images/large/nejmoa2031049_f1.jpg" height="1394" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Least-Squares Mean Percent Change from Baseline in the Calculated Low-Density Lipoprotein Cholesterol Level at Week 16.</div><div class="notes"><div role="doc-footnote">The least-squares mean and standard errors are taken from a mixed-effect model with a repeated-measures approach, with the categorical fixed effects of treatment (evinacumab or placebo), randomization strata (receipt of a high-intensity statin [yes or no] and presence of heterozygous familial hypercholesterolemia [yes or no]), time point up to week 16, treatment-by-time point interaction, and strata-by-time point interaction, as well as continuous fixed covariates of the calculated low-density lipoprotein (LDL) cholesterol level at baseline and baseline LDL cholesterol level-by-time point interaction. 𝙸 bars indicate standard errors.</div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2031049_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2031049_t3.jpg"><img src="/cms/10.1056/NEJMoa2031049/asset/43607283-aa16-45b6-a24d-05b548a846c2/assets/images/large/nejmoa2031049_t3.jpg" height="1119" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Trial Group</th><th class="txxx-borders">No. of Patients</th><th class="txxx-borders">Change from Baseline in LDL Cholesterol Level</th><th class="txxx-borders">Difference vs. Placebo (95% CI)</th><th class="txxr-borders">P Value</th></tr><tr class="head3" data-type="row head3" data-xml-valign="top"><td class="xxlx-borders hanging02">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><th class="xxxx-borders">percent</th><th class="xxxx-borders">percentage points</th><td class="xxxr-borders">&nbsp;</td></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Subcutaneous regimen</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Evinacumab</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">450 mg weekly</td><td class="xxxx-borders shading">40</td><td class="xxxx-borders shading">–47.2±6.2</td><td class="xxxx-borders shading">–56.0±9.0 (–73.7 to –38.3)</td><td class="xxxr-borders shading">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">300 mg weekly</td><td class="xxxx-borders">42</td><td class="xxxx-borders">–44.0±6.3</td><td class="xxxx-borders">–52.9±9.0 (–70.7 to –35.1)</td><td class="xxxr-borders">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">300 mg every 2 wk</td><td class="xxxx-borders shading">39</td><td class="xxxx-borders shading">–29.7±6.4</td><td class="xxxx-borders shading">–38.5±9.1 (–56.5 to –20.6)</td><td class="xxxr-borders shading">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Placebo, weekly</td><td class="xxxx-borders">39</td><td class="xxxx-borders">8.8±6.4</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Intravenous regimen</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Evinacumab</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">15 mg/kg every 4 wk</td><td class="xxxx-borders shading">38</td><td class="xxxx-borders shading">–49.9±6.1</td><td class="xxxx-borders shading">–50.5±9.0 (–68.4 to –32.6)</td><td class="xxxr-borders shading">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">5 mg/kg every 4 wk</td><td class="xxxx-borders">35</td><td class="xxxx-borders">–23.5±6.6</td><td class="xxxx-borders">–24.2±9.3 (–42.6 to –5.7)<a href="#t3fn2" role="doc-noteref">†</a></td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Placebo, every 4 wk</td><td class="xbxx-borders shading">33</td><td class="xbxx-borders shading">0.6±6.6</td><td class="xbxx-borders shading">—</td><td class="xbxr-borders shading">—</td></tr></tbody></table></div><figcaption><div class="caption">Change from Baseline in the Calculated LDL Cholesterol Level at Week 16 in Patients with Refractory Hypercholesterolemia.<a href="#t3fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">Plus–minus values are least-squares means ±SE. Data are shown for the intention-to-treat population.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t3fn2" role="paragraph">The width of the 95% confidence interval has not been adjusted for multiplicity and cannot be used to infer treatment effects.</div></div></div></figcaption></figure></div></section><section id="sec-2-3-2"><h4>Intravenous Evinacumab</h4><div role="paragraph">At week 16, the change from baseline in the LDL cholesterol level was –49.9% with intravenous evinacumab at a dose of 15 mg per kilogram, as compared with 0.6% with placebo, with a least-squares mean difference of –50.5 percentage points (P&lt;0.001) (<a href="#f1">Figure 1</a> and <a href="#t3">Table 3</a>). The change was –23.5% with intravenous evinacumab at a dose of 5 mg per kilogram, with a least-squares mean difference (vs. placebo) of –24.2 percentage points (<a href="#f1">Figure 1</a> and <a href="#t3">Table 3</a>). The reduction in the LDL cholesterol level with the two intravenous-evinacumab regimens was observed as early as the first postbaseline lipid assessment (week 2) and was maintained through week 16.</div></section></section><section id="sec-2-4"><h3>Secondary Efficacy Analysis</h3><div role="paragraph">Lipid levels were substantially lower with subcutaneous and intravenous evinacumab than with placebo (Tables S1 and S2). With the exception of the lipoprotein(a) level, all atherogenic lipoprotein levels decreased in a dose-dependent manner. At week 16, the change from baseline in the HDL cholesterol level was −27.9%, −30.3%, and −19.5% with subcutaneous evinacumab at a dose of 450 mg weekly, 300 mg weekly, and 300 mg every 2 weeks, respectively, as compared with −1.7% with subcutaneous placebo. In addition, at week 16, the change from baseline in the mean HDL cholesterol level was −31.4% and −14.9% with intravenous evinacumab at a dose of 15 mg per kilogram and 5 mg per kilogram, respectively, as compared with 1.9% with intravenous placebo.</div></section><section id="sec-2-5"><h3>Safety</h3><div role="paragraph">During the double-blind treatment period, adverse events occurred in 68%, 67%, and 82% of the patients who received subcutaneous evinacumab at a dose of 450 mg weekly, 300 mg weekly, and 300 mg every 2 weeks, respectively, as compared with 54% of the patients who received subcutaneous placebo (<a href="#t4">Table 4</a>). Adverse events that occurred in at least 5% of the patients in the subcutaneous-treatment groups are described in Table S3. Adverse events that occurred in at least 5% of the patients who received subcutaneous evinacumab (any of the three regimens) and occurred more frequently with subcutaneous evinacumab than with subcutaneous placebo included urinary tract infection (11% vs. 8%), injection-site erythema (6% vs. 3%), arthralgia (5% vs. 3%), and myalgia (5% vs. 0%).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 4</div><nav><a href="#t4" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2031049_t4.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t4" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t4" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2031049_t4.jpg"><img src="/cms/10.1056/NEJMoa2031049/asset/6cbe70fd-937f-4666-a090-dc6cfbaf1167/assets/images/large/nejmoa2031049_t4.jpg" height="1834" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Trial Group</th><th class="txxx-borders">No. of Patients</th><th class="txxx-borders">Any Adverse Event</th><th class="txxx-borders">≥1 Serious Adverse Event</th><th class="txxx-borders">≥1 Adverse Event Resulting in Treatment Discontinuation</th><th class="txxr-borders">Any Adverse Event Resulting in Death</th></tr><tr class="headc" data-type="row headc" data-xml-valign="top"><td class="xxlx-borders hanging02">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><th class="xxxr-borders" colspan="4"><span><i>number of patients (percent)</i></span></th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Subcutaneous regimen</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Evinacumab</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">450 mg weekly</td><td class="xxxx-borders shading">40</td><td class="xxxx-borders shading">27 (68)<a href="#t4fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">3 (8)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">300 mg weekly</td><td class="xxxx-borders">42</td><td class="xxxx-borders">28 (67)<a href="#t4fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">3 (7)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">300 mg every 2 wk</td><td class="xxxx-borders shading">39</td><td class="xxxx-borders shading">32 (82)<a href="#t4fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">2 (5)</td><td class="xxxx-borders shading">2 (5)</td><td class="xxxr-borders shading">1 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Placebo, weekly</td><td class="xxxx-borders">39</td><td class="xxxx-borders">21 (54)<a href="#t4fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">3 (8)</td><td class="xxxx-borders">2 (5)</td><td class="xxxr-borders">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Intravenous regimen</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Evinacumab</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">15 mg/kg every 4 wk</td><td class="xxxx-borders shading">37</td><td class="xxxx-borders shading">31 (84)<a href="#t4fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">6 (16)</td><td class="xxxx-borders shading">2 (5)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">5 mg/kg every 4 wk</td><td class="xxxx-borders">36</td><td class="xxxx-borders">27 (75)<a href="#t4fn7" role="doc-noteref">**</a></td><td class="xxxx-borders">2 (6)</td><td class="xxxx-borders">2 (6)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Placebo, every 4 wk</td><td class="xbxx-borders shading">33</td><td class="xbxx-borders shading">23 (70)<a href="#t4fn8" role="doc-noteref">††</a></td><td class="xbxx-borders shading">1 (3)</td><td class="xbxx-borders shading">1 (3)</td><td class="xbxr-borders shading">0</td></tr></tbody></table></div><figcaption><div class="caption">Overall Safety Profile of Subcutaneous and Intravenous Evinacumab during the Double-Blind Treatment Period in Patients with Refractory Hypercholesterolemia.<a href="#t4fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t4fn1" role="paragraph">Data are shown for the double-blind safety analysis population, which included 266 patients.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t4fn2" role="paragraph">The most common adverse events that occurred with subcutaneous evinacumab at a dose of 450 mg weekly were diarrhea (8%), headache (10%), influenza-like illness (8%), injection-site erythema (10%), nausea (10%), nasopharyngitis (10%), and urinary tract infection (10%).</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t4fn3" role="paragraph">The most common adverse events that occurred with subcutaneous evinacumab at a dose of 300 mg weekly were chest pain (7%), fall (7%), headache (7%), injection-site hemorrhage (7%), injection-site hematoma (7%), back pain (10%), nasopharyngitis (10%), oropharyngeal pain (10%), and urinary tract infection (10%).</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t4fn4" role="paragraph">The most common adverse events that occurred with subcutaneous evinacumab at a dose of 300 mg every 2 weeks were arthralgia (8%), back pain (8%), myalgia (8%), constipation (10%), nausea (10%), nasopharyngitis (10%), and urinary tract infection (13%).</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t4fn5" role="paragraph">The most common adverse events that occurred with subcutaneous placebo were diarrhea (8%), fatigue (8%), nausea (8%), urinary tract infection (8%), headache (10%), back pain (13%), dizziness (13%), and nasopharyngitis (15%).</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t4fn6" role="paragraph">The most common adverse events that occurred with intravenous evinacumab at a dose of 15 mg per kilogram every 4 weeks were asthenia (8%), dizziness (8%), hypertension (14%), and nasopharyngitis (16%).</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="t4fn7" role="paragraph">The most common adverse events that occurred with intravenous evinacumab at a dose of 5 mg per kilogram every 4 weeks were influenza-like illness (8%), pain in an arm or leg (8%), nasopharyngitis (8%), fatigue (11%), and myalgia (11%).</div></div><div role="doc-footnote" data-has="label"><div class="label">††</div><div id="t4fn8" role="paragraph">The most common adverse events that occurred with intravenous placebo were arthralgia (9%), influenza-like illness (9%), myalgia (12%), and headache (18%).</div></div></div></figcaption></figure></div><div role="paragraph">During the double-blind treatment period, adverse events occurred in 84% and 75% of the patients who received intravenous evinacumab at a dose of 15 mg per kilogram and 5 mg per kilogram, respectively, as compared with 70% of the patients who received intravenous placebo (<a href="#t4">Table 4</a>). Adverse events that occurred in at least 5% of the patients who received intravenous evinacumab (either of the two regimens) and occurred more frequently with intravenous evinacumab than with intravenous placebo included abdominal pain (6% vs. 0%), back pain (7% vs. 6%), dizziness (7% vs. 0%), fatigue (7% vs. 6%), pain in an arm or leg (7% vs. 6%), nausea (7% vs. 0%), and nasopharyngitis (12% vs. 6%).</div><div role="paragraph">In patients who received subcutaneous or intravenous evinacumab, few high-grade adverse events were observed. Overall, there were no clinically significant differences between the subcutaneous-treatment groups and the intravenous-treatment groups with respect to serious adverse events, adverse events resulting in treatment discontinuation, or adverse events of special interest that occurred during the double-blind treatment period.</div><div role="paragraph">In the subcutaneous-treatment groups, the only adverse event resulting in treatment discontinuation that was considered by the investigator to be related to the trial drug was dyspnea, which occurred with subcutaneous evinacumab at a dose of 300 mg every 2 weeks and resolved fully. Adverse events resulting in death occurred in one patient who was treated with subcutaneous evinacumab at a dose of 300 mg weekly (heart failure or cardiogenic shock) and one patient who was treated with subcutaneous evinacumab at a dose of 300 mg every 2 weeks (sudden cardiac death). These events occurred in patients with underlying heart disease and were not considered by the investigator to be related to the trial drug. In the intravenous-treatment groups, the only adverse event resulting in treatment discontinuation that was considered by the investigator to be related to the trial drug was anaphylactic reaction (an adverse event of special interest), which occurred with the second dose of intravenous evinacumab at a dose of 15 mg per kilogram. This event, which occurred in a patient with a relevant medical history of asthma and seasonal allergies, involved multiple symptoms, including dizziness, chest pressure, tingling in the arms and legs, shortness of breath, pruritus, decreased blood pressure, and increased heart rate. The evinacumab infusion was discontinued and the event resolved on the same day after treatment with oral diphenhydramine. No patients who received intravenous treatment had adverse events resulting in death.</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">In this phase 2 trial, we found that the use of evinacumab reduced levels of LDL cholesterol and atherogenic lipoproteins in patients with refractory hypercholesterolemia. The response to treatment, or reduction in the LDL cholesterol level, with subcutaneous and intravenous evinacumab was observed as early as the first postbaseline lipid assessment (week 2) and was maintained through week 16. Serious adverse events were observed in 3 to 16% of patients across trial groups.</div><div role="paragraph">To reduce the risk of atherosclerotic cardiovascular disease, patients who have heterozygous familial hypercholesterolemia are typically treated with lipid-lowering therapies, which may include a statin, ezetimibe, and a PCSK9 inhibitor.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9" id="body-ref-r9-2" href-manipulated="true" aria-label="Reference 9">9</a></sup> Although each standard-of-care therapy contributes to overall lowering of the LDL cholesterol level, there remains a residual unmet need among patients who have a high baseline LDL cholesterol level.<sup><a href="#core-r24" role="doc-biblioref" data-xml-rid="r24 r25" id="body-ref-r25-1" href-manipulated="true">24,25</a></sup> This is particularly relevant in the context of the 2019 ESC–EAS lipid-management guidelines, which specify a target LDL cholesterol level of less than 55 mg per deciliter for patients with very high risk for atherosclerotic cardiovascular disease<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9" id="body-ref-r9-3" href-manipulated="true" aria-label="Reference 9">9</a></sup>; the 2016 ESC–EAS guidelines and the 2018 ACC–AHA guidelines recommended a target LDL cholesterol level of less than 70 mg per deciliter in patients with very high risk for atherosclerotic cardiovascular disease.<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10 r26" id="body-ref-r26" href-manipulated="true">10,26</a></sup> In addition, some patients with heterozygous familial hypercholesterolemia may have adverse events associated with standard-of-care lipid-lowering therapies, which limit the optimization of treatment regimens.<sup><a href="#core-r25" role="doc-biblioref" data-xml-rid="r25 r27 r28" id="body-ref-r28" href-manipulated="true">25,27,28</a></sup> Data from a pooled analysis of eight phase 3 ODYSSEY trials involving 4629 patients with hypercholesterolemia (with or without heterozygous familial hypercholesterolemia) showed that 41% were not receiving a high-dose statin, with a frequent investigator-assessed reason (in 32% of cases) being statin-associated muscle symptoms, an increased creatine kinase level, or both.<sup><a href="#core-r29" role="doc-biblioref" data-xml-rid="r29" id="body-ref-r29" href-manipulated="true" aria-label="Reference 29">29</a></sup></div><div role="paragraph">The use of PCSK9 inhibitors in combination with other lipid-lowering therapies reduces the risk of major adverse cardiovascular events and reduces the LDL cholesterol level by 50 to 60%.<sup><a href="#core-r30" role="doc-biblioref" data-xml-rid="r30 r31" id="body-ref-r31" href-manipulated="true">30,31</a></sup> However, a real-world study involving 204 patients with heterozygous familial hypercholesterolemia and very high risk for cardiovascular disease showed that only 39% had an LDL cholesterol level of less than 55 mg per deciliter despite treatment with PCSK9 inhibitors.<sup><a href="#core-r25" role="doc-biblioref" data-xml-rid="r25" id="body-ref-r25-3" href-manipulated="true" aria-label="Reference 25">25</a></sup> Of the 143 patients who were receiving triple therapy (a high-intensity statin, ezetimibe, and a PCSK9 inhibitor), 45% had an LDL cholesterol level of less than 55 mg per deciliter.<sup><a href="#core-r25" role="doc-biblioref" data-xml-rid="r25" id="body-ref-r25-4" href-manipulated="true" aria-label="Reference 25">25</a></sup> Given the significant reduction in levels of LDL cholesterol and atherogenic lipoproteins observed in our trial, the addition of evinacumab to standard-of-care lipid-lowering therapies that include PCSK9 inhibitors in patients with refractory hypercholesterolemia may potentially facilitate a greater number of patients attaining guideline-defined target LDL cholesterol levels and, in doing so, reduce the risk of cardiovascular events and overall mortality. In contrast to cholesterylester transfer protein and apolipoprotein C3 inhibition, which results in a small reduction in the apolipoprotein B level as compared with the reduction in the LDL cholesterol level, ANGPTL3 inhibition lowers both the LDL cholesterol level and the apolipoprotein B level substantially.<sup><a href="#core-r32" role="doc-biblioref" data-xml-rid="r32 r33" id="body-ref-r33" href-manipulated="true">32,33</a></sup> In view of the strong genetic data supporting a decrease in the risk of cardiovascular disease proportional to the reduction in the apolipoprotein B level,<sup><a href="#core-r34" role="doc-biblioref" data-xml-rid="r34" id="body-ref-r34" href-manipulated="true" aria-label="Reference 34">34</a></sup> the results of this trial support a potential cardiovascular-disease benefit of ANGPTL3 inhibition.</div><div role="paragraph">Treatment with subcutaneous or intravenous evinacumab prompted a reduction in the HDL cholesterol level. Reduction in the HDL cholesterol level has been observed in dyslipidemic or normolipidemic mouse models after targeted inactivation of ANGPTL3; this reduction is due to derepression of endothelial lipase, which is a consequence of ANGPTL3 blockade.<sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15 r21" id="body-ref-r21-2" href-manipulated="true">15,21</a></sup> In the phase 3 ELIPSE HoFH trial involving patients with homozygous familial hypercholesterolemia, there was a 29.6% decrease in the HDL cholesterol level after inhibition of ANGPTL3 with evinacumab, as compared with a 0.8% increase with placebo.<sup><a href="#core-r22" role="doc-biblioref" data-xml-rid="r22" id="body-ref-r22-2" href-manipulated="true" aria-label="Reference 22">22</a></sup> The importance of the reduction in the HDL cholesterol level observed with evinacumab remains to be fully elucidated, but in patients with a naturally occurring genetic ANGPTL3 deficiency, low HDL cholesterol levels are not associated with an increased risk of cardiovascular disease.<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18" id="body-ref-r18-3" href-manipulated="true" aria-label="Reference 18">18</a></sup></div><div role="paragraph">Elevated levels of triglycerides have been reported to be an independent risk factor for atherosclerotic cardiovascular disease.<sup><a href="#core-r35" role="doc-biblioref" data-xml-rid="r35" id="body-ref-r35" href-manipulated="true" aria-label="Reference 35">35</a></sup> Many studies show that PCSK9 inhibitors induce moderate reductions in levels of triglycerides that are not always statistically significant.<sup><a href="#core-r36" role="doc-biblioref" data-xml-rid="r36" id="body-ref-r36" href-manipulated="true" aria-label="Reference 36">36</a></sup> Our trial shows that the use of subcutaneous or intravenous evinacumab could potentially lead to a clinically significant reduction in the risk of cardiovascular disease by substantially reducing levels of LDL cholesterol and triglycerides.</div><div role="paragraph">The reductions in the LDL cholesterol level observed with subcutaneous evinacumab (450 mg weekly and 300 mg weekly) were similar to the reduction seen with intravenous evinacumab at a dose of 15 mg per kilogram every 4 weeks. The efficacy of this intravenous evinacumab regimen has been shown previously in the pivotal phase 3 ELIPSE HoFH trial.<sup><a href="#core-r22" role="doc-biblioref" data-xml-rid="r22" id="body-ref-r22-3" href-manipulated="true" aria-label="Reference 22">22</a></sup> Because intravenous administration occurs in a health care setting, it ensures greater adherence to treatment. However, subcutaneous administration may be a viable alternative, given that some patients may prefer to administer the treatment at home despite the increased frequency of dosing, in order to prevent loss of work productivity and personal time.<sup><a href="#core-r37" role="doc-biblioref" data-xml-rid="r37 r38" id="body-ref-r38" href-manipulated="true">37,38</a></sup> Moreover, subcutaneous administration is often preferred by health care providers, because it lowers health care costs related to drug delivery.<sup><a href="#core-r37" role="doc-biblioref" data-xml-rid="r37" id="body-ref-r37-2" href-manipulated="true" aria-label="Reference 37">37</a></sup></div><div role="paragraph">The limitations of this trial include the small sample size and the short treatment duration. Moreover, the racial backgrounds of the patients were not as diverse as we had intended. Thus, robust conclusions pertaining to the long-term safety of evinacumab cannot be established. In addition, we noted that the percentage of patients who were taking ezetimibe appeared to be low, both among those assigned to receive subcutaneous treatment (30%) and among those assigned to receive intravenous treatment (38%). The percentage of patients who were taking ezetimibe in our trial was higher than the percentage of patients who were taking ezetimibe at baseline (24%) in the ODYSSEY HIGH FH trial, which assessed alirocumab in patients with heterozygous familial hypercholesterolemia, but was lower than the percentage of patients with severe heterozygous familial hypercholesterolemia who were taking ezetimibe (62%) in TAUSSIG (Trial Assessing Long-Term Use of PCSK9 Inhibition in Subjects with Genetic LDL Disorders), which assessed evolocumab in patients with familial hypercholesterolemia.<sup><a href="#core-r39" role="doc-biblioref" data-xml-rid="r39 r40" id="body-ref-r40" href-manipulated="true">39,40</a></sup></div><div role="paragraph">In conclusion, results of this trial and previous studies suggest that evinacumab is effective in lowering LDL cholesterol levels in patients with refractory hypercholesterolemia, including homozygous familial hypercholesterolemia,<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19 r22" id="body-ref-r22-4" href-manipulated="true">19,22</a></sup> refractory heterozygous familial hypercholesterolemia, and hypercholesterolemia of an undetermined cause.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="published/updated" role="paragraph">This article was published on November 15, 2020, at NEJM.org.</div><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by <span class="named-content" data-type="funder">Regeneron</span> Pharmaceuticals.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank the patients and their families who were involved in the trial; Andrew Gewitz, Ph.D., of Regeneron Pharmaceuticals for his contributions to the pharmacokinetic and pharmacodynamic analyses; and Michele Damo, Pharm.D., and Atif Riaz, Ph.D., of Prime Global (Knutsford, United Kingdom) for providing medical-writing assistance and editorial support on earlier drafts of the manuscript under the direction of the authors.</div><div role="paragraph">This article is dedicated to the memory of Daniel A. Gipe, M.D., who died prematurely and unexpectedly and to whom we are all profoundly indebted, not only for his contributions to this manuscript but also for his significant personal contributions to the recent advancements in the fields that are described here.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2031049_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2031049/suppl_file/nejmoa2031049_protocol.pdf" download="nejmoa2031049_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2031049_protocol.pdf" data-doi="10.1056/NEJMoa2031049">Download</a></li><li>2.32 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2031049_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2031049/suppl_file/nejmoa2031049_appendix.pdf" download="nejmoa2031049_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2031049_appendix.pdf" data-doi="10.1056/NEJMoa2031049">Download</a></li><li>806.45 KB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2031049_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2031049/suppl_file/nejmoa2031049_disclosures.pdf" download="nejmoa2031049_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2031049_disclosures.pdf" data-doi="10.1056/NEJMoa2031049">Download</a></li><li>284.20 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2031049_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2031049/suppl_file/nejmoa2031049_data-sharing.pdf" download="nejmoa2031049_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2031049_data-sharing.pdf" data-doi="10.1056/NEJMoa2031049">Download</a></li><li>68.04 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies: a consensus statement from the European Atherosclerosis Society Consensus Panel. <em>Eur Heart J</em> 2017;38:2459-2472.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/eurheartj/ehx144" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28444290/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000408001800012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Low-density+lipoproteins+cause+atherosclerotic+cardiovascular+disease.+1.+Evidence+from+genetic%2C+epidemiologic%2C+and+clinical+studies%3A+a+consensus+statement+from+the+European+Atherosclerosis+Society+Consensus+Panel.&amp;publication_year=2017&amp;journal=Eur+Heart+J&amp;pages=2459-2472&amp;doi=10.1093%2Feurheartj%2Fehx144&amp;pmid=28444290" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Khera AV, Won H-H, Peloso GM, et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. <em>J Am Coll Cardiol</em> 2016;67:2578-2589.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r2" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jacc.2016.03.520" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27050191/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000377271300003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Diagnostic+yield+and+clinical+utility+of+sequencing+familial+hypercholesterolemia+genes+in+patients+with+severe+hypercholesterolemia.&amp;publication_year=2016&amp;journal=J+Am+Coll+Cardiol&amp;pages=2578-2589&amp;doi=10.1016%2Fj.jacc.2016.03.520&amp;pmid=27050191" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r2" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r2-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] deciliter (4.91 mmol per liter) or higher. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r2-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] patients with severe hypercholesterolemia. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r2-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] to elevated LDL cholesterol levels. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects. <em>J Am Coll Cardiol</em> 2020;75:2553-2566.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jacc.2020.03.057" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32439005/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000536789100005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Worldwide+prevalence+of+familial+hypercholesterolemia%3A+meta-analyses+of+11+million+subjects.&amp;publication_year=2020&amp;journal=J+Am+Coll+Cardiol&amp;pages=2553-2566&amp;doi=10.1016%2Fj.jacc.2020.03.057&amp;pmid=32439005" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r3-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] with severe hypercholesterolemia was 7.2%. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r3-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] suggests that 1 in 313 people is affected. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r3-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] the prevalence in the general population. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Gidding SS, Champagne MA, de Ferranti SD, et al. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. <em>Circulation</em> 2015;132:2167-2192.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1161/CIR.0000000000000297" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26510694/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000366187100010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+agenda+for+familial+hypercholesterolemia%3A+a+scientific+statement+from+the+American+Heart+Association.&amp;publication_year=2015&amp;journal=Circulation&amp;pages=2167-2192&amp;doi=10.1161%2FCIR.0000000000000297&amp;pmid=26510694" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] an elevated plasma LDL cholesterol level. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] coverage support, and adverse events. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">McGowan MP, Hosseini Dehkordi SH, Moriarty PM, Duell PB. Diagnosis and treatment of heterozygous familial hypercholesterolemia. <em>J Am Heart Assoc</em> 2019;8(24):e013225-e013225.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1161/JAHA.119.013225" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31838973/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000514326200002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Diagnosis+and+treatment+of+heterozygous+familial+hypercholesterolemia.&amp;publication_year=2019&amp;journal=J+Am+Heart+Assoc&amp;pages=e013225-e013225&amp;doi=10.1161%2FJAHA.119.013225&amp;pmid=31838973" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. <em>Eur Heart J</em> 2013;34:3478-390a.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/eurheartj/eht273" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23956253/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000328393500009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Familial+hypercholesterolaemia+is+underdiagnosed+and+undertreated+in+the+general+population%3A+guidance+for+clinicians+to+prevent+coronary+heart+disease%3A+consensus+statement+of+the+European+Atherosclerosis+Society.&amp;publication_year=2013&amp;journal=Eur+Heart+J&amp;pages=3478-390a&amp;doi=10.1093%2Feurheartj%2Feht273&amp;pmid=23956253" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Gallo A, Charriere S, Vimont A, et al. SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia. <em>Atherosclerosis</em> 2020;306:41-49.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.atherosclerosis.2020.06.011" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32688103/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000568235700007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=SAFEHEART+risk-equation+and+cholesterol-year-score+are+powerful+predictors+of+cardiovascular+events+in+French+patients+with+familial+hypercholesterolemia.&amp;publication_year=2020&amp;journal=Atherosclerosis&amp;pages=41-49&amp;doi=10.1016%2Fj.atherosclerosis.2020.06.011&amp;pmid=32688103" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Khera AV, Chaffin M, Zekavat SM, et al. Whole-genome sequencing to characterize monogenic and polygenic contributions in patients hospitalized with early-onset myocardial infarction. <em>Circulation</em> 2019;139:1593-1602.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1161/CIRCULATIONAHA.118.035658" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30586733/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000469319000009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Whole-genome+sequencing+to+characterize+monogenic+and+polygenic+contributions+in+patients+hospitalized+with+early-onset+myocardial+infarction.&amp;publication_year=2019&amp;journal=Circulation&amp;pages=1593-1602&amp;doi=10.1161%2FCIRCULATIONAHA.118.035658&amp;pmid=30586733" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <em>Eur Heart J</em> 2020;41:111-188.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/eurheartj/ehz455" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31504418/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000605984300013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2019+ESC%2FEAS+guidelines+for+the+management+of+dyslipidaemias%3A+lipid+modification+to+reduce+cardiovascular+risk.&amp;publication_year=2020&amp;journal=Eur+Heart+J&amp;pages=111-188&amp;doi=10.1093%2Feurheartj%2Fehz455&amp;pmid=31504418" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] cardiovascular disease, respectively. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] a statin, ezetimibe, and a PCSK9 inhibitor. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] for atherosclerotic cardiovascular disease </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. <em>Circulation</em> 2019;139(25):e1082-e1143.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30586774/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000471794100005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2018+AHA%2FACC%2FAACVPR%2FAAPA%2FABC%2FACPM%2FADA%2FAGS%2FAPhA%2FASPC%2FNLA%2FPCNA+guideline+on+the+management+of+blood+cholesterol%3A+a+report+of+the+American+College+of+Cardiology%2FAmerican+Heart+Association+task+force+on+clinical+practice+guidelines.&amp;publication_year=2019&amp;journal=Circulation&amp;pages=e1082-e1143&amp;pmid=30586774" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] for atherosclerotic cardiovascular disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] for atherosclerotic cardiovascular disease. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Wang A, Richhariya A, Gandra SR, et al. Systematic review of low-density lipoprotein cholesterol apheresis for the treatment of familial hypercholesterolemia. <em>J Am Heart Assoc</em> 2016;5(7):e003294-e003294.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1161/JAHA.116.003294" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27385428/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000386713800022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Systematic+review+of+low-density+lipoprotein+cholesterol+apheresis+for+the+treatment+of+familial+hypercholesterolemia.&amp;publication_year=2016&amp;journal=J+Am+Heart+Assoc&amp;pages=e003294-e003294&amp;doi=10.1161%2FJAHA.116.003294&amp;pmid=27385428" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Ishigaki Y, Kawagishi N, Hasegawa Y, et al. Liver transplantation for homozygous familial hypercholesterolemia. <em>J Atheroscler Thromb</em> 2019;26:121-127.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.5551/jat.RV17029" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30555131/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000457404700003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Liver+transplantation+for+homozygous+familial+hypercholesterolemia.&amp;publication_year=2019&amp;journal=J+Atheroscler+Thromb&amp;pages=121-127&amp;doi=10.5551%2Fjat.RV17029&amp;pmid=30555131" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Tikka A, Jauhiainen M. The role of ANGPTL3 in controlling lipoprotein metabolism. <em>Endocrine</em> 2016;52:187-193.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s12020-015-0838-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26754661/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000373961700003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+role+of+ANGPTL3+in+controlling+lipoprotein+metabolism.&amp;publication_year=2016&amp;journal=Endocrine&amp;pages=187-193&amp;doi=10.1007%2Fs12020-015-0838-9&amp;pmid=26754661" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Kersten S. Angiopoietin-like 3 in lipoprotein metabolism. <em>Nat Rev Endocrinol</em> 2017;13:731-739.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nrendo.2017.119" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28984319/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000414767300017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Angiopoietin-like+3+in+lipoprotein+metabolism.&amp;publication_year=2017&amp;journal=Nat+Rev+Endocrinol&amp;pages=731-739&amp;doi=10.1038%2Fnrendo.2017.119&amp;pmid=28984319" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Musunuru K, Pirruccello JP, Do R, et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. <em>N Engl J Med</em> 2010;363:2220-2227.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r15" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_16_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2031049&amp;key=10.1056%2FNEJMoa1002926&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20942659/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000284832900009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Exome+sequencing%2C+ANGPTL3+mutations%2C+and+familial+combined+hypolipidemia.&amp;publication_year=2010&amp;journal=N+Engl+J+Med&amp;pages=2220-2227&amp;doi=10.1056%2FNEJMoa1002926&amp;pmid=20942659" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r15" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r17" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] lipoprotein lipase and endothelial lipase. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] which is a consequence of ANGPTL3 blockade. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Adam RC, Mintah IJ, Alexa-Braun CA, et al. Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance. <em>J Lipid Res</em> 2020;61:1271-1286.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32646941/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Angiopoietin-like+protein+3+governs+LDL-cholesterol+levels+through+endothelial+lipase-dependent+VLDL+clearance.&amp;publication_year=2020&amp;pages=1271-1286&amp;pmid=32646941" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Wu L, Soundarapandian MM, Castoreno AB, Millar JS, Rader DJ. LDL-cholesterol reduction by ANGPTL3 inhibition in mice is dependent on endothelial lipase. <em>Circ Res</em> 2020;127:1112-1114.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1161/CIRCRESAHA.120.317128" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32808882/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000576633500012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=LDL-cholesterol+reduction+by+ANGPTL3+inhibition+in+mice+is+dependent+on+endothelial+lipase.&amp;publication_year=2020&amp;journal=Circ+Res&amp;pages=1112-1114&amp;doi=10.1161%2FCIRCRESAHA.120.317128&amp;pmid=32808882" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Dewey FE, Gusarova V, Dunbar RL, et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. <em>N Engl J Med</em> 2017;377:211-221.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r18" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_19_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2031049&amp;key=10.1056%2FNEJMoa1612790&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28538136/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000405777600005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Genetic+and+pharmacologic+inactivation+of+ANGPTL3+and+cardiovascular+disease.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=211-221&amp;doi=10.1056%2FNEJMoa1612790&amp;pmid=28538136" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r18" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r18-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] high-density lipoprotein (HDL) cholesterol. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] than the risk in the general population. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] increased risk of cardiovascular disease. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Gaudet D, Gipe DA, Pordy R, et al. ANGPTL3 inhibition in homozygous familial hypercholesterolemia. <em>N Engl J Med</em> 2017;377:296-297.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r19" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_20_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2031049&amp;key=10.1056%2FNEJMc1705994&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28723334/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000405777600017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=ANGPTL3+inhibition+in+homozygous+familial+hypercholesterolemia.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=296-297&amp;doi=10.1056%2FNEJMc1705994&amp;pmid=28723334" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r19" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r21-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] mechanism independent of the LDL receptor. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] homozygous familial hypercholesterolemia, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Banerjee P, Chan K-C, Tarabocchia M, et al. Functional analysis of LDLR (low-density lipoprotein receptor) variants in patient lymphocytes to assess the effect of evinacumab in homozygous familial hypercholesterolemia patients with a spectrum of LDLR activity. <em>Arterioscler Thromb Vasc Biol</em> 2019;39:2248-2260.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1161/ATVBAHA.119.313051" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31578082/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000494483700013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Functional+analysis+of+LDLR+%28low-density+lipoprotein+receptor%29+variants+in+patient+lymphocytes+to+assess+the+effect+of+evinacumab+in+homozygous+familial+hypercholesterolemia+patients+with+a+spectrum+of+LDLR+activity.&amp;publication_year=2019&amp;journal=Arterioscler+Thromb+Vasc+Biol&amp;pages=2248-2260&amp;doi=10.1161%2FATVBAHA.119.313051&amp;pmid=31578082" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Gusarova V, Alexa CA, Wang Y, et al. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. <em>J Lipid Res</em> 2015;56:1308-1317.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r21" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1194/jlr.M054890" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25964512/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000356834700008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=ANGPTL3+blockade+with+a+human+monoclonal+antibody+reduces+plasma+lipids+in+dyslipidemic+mice+and+monkeys.&amp;publication_year=2015&amp;journal=J+Lipid+Res&amp;pages=1308-1317&amp;doi=10.1194%2Fjlr.M054890&amp;pmid=25964512" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r21" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r21-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] mechanism independent of the LDL receptor. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] which is a consequence of ANGPTL3 blockade. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for homozygous familial hypercholesterolemia. <em>N Engl J Med</em> 2020;383:711-720.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r22" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_23_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2031049&amp;key=10.1056%2FNEJMoa2004215&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32813947/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000563818700011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Evinacumab+for+homozygous+familial+hypercholesterolemia.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=711-720&amp;doi=10.1056%2FNEJMoa2004215&amp;pmid=32813947" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r22" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r22-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] (&lt;2% LDL receptor activity). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] compared with a 0.8% increase with placebo. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] in the pivotal phase 3 ELIPSE HoFH trial. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] homozygous familial hypercholesterolemia, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. <em>Clin Chem</em> 1972;18:499-502.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/clinchem/18.6.499" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/4337382/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1972M604800001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Estimation+of+the+concentration+of+low-density+lipoprotein+cholesterol+in+plasma%2C+without+use+of+the+preparative+ultracentrifuge.&amp;publication_year=1972&amp;journal=Clin+Chem&amp;pages=499-502&amp;doi=10.1093%2Fclinchem%2F18.6.499&amp;pmid=4337382" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">van Delden XM, Huijgen R, Wolmarans KH, et al. LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: minority at target despite large reductions in LDL-C. <em>Atherosclerosis</em> 2018;277:327-333.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.atherosclerosis.2018.06.820" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30270067/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000445908000050" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=LDL-cholesterol+target+achievement+in+patients+with+heterozygous+familial+hypercholesterolemia+at+Groote+Schuur+Hospital%3A+minority+at+target+despite+large+reductions+in+LDL-C.&amp;publication_year=2018&amp;journal=Atherosclerosis&amp;pages=327-333&amp;doi=10.1016%2Fj.atherosclerosis.2018.06.820&amp;pmid=30270067" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Rallidis LS, Liberopoulos EN, Vlachopoulos C, et al. Very high-risk familial hypercholesterolaemia patients in real life: the remaining gap in achieving the current LDL-C targets despite the use of PCSK9 inhibitors. <em>Atherosclerosis</em> 2020;309:67-69.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r25" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.atherosclerosis.2020.07.018" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32859385/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000573866600010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Very+high-risk+familial+hypercholesterolaemia+patients+in+real+life%3A+the+remaining+gap+in+achieving+the+current+LDL-C+targets+despite+the+use+of+PCSK9+inhibitors.&amp;publication_year=2020&amp;journal=Atherosclerosis&amp;pages=67-69&amp;doi=10.1016%2Fj.atherosclerosis.2020.07.018&amp;pmid=32859385" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r25" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r25-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] have a high baseline LDL cholesterol level. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r28" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] the optimization of treatment regimens. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r25-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] despite treatment with PCSK9 inhibitors. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r25-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] level of less than 55 mg per deciliter. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. <em>Eur Heart J</em> 2016;37:2999-3058.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/eurheartj/ehw272" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27567407/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000387990800012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2016+ESC%2FEAS+guidelines+for+the+management+of+dyslipidaemias.&amp;publication_year=2016&amp;journal=Eur+Heart+J&amp;pages=2999-3058&amp;doi=10.1093%2Feurheartj%2Fehw272&amp;pmid=27567407" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="r27" class="citations"><div class="citation"><div class="citation-content">Raal FJ, Hovingh GK, Catapano AL. Familial hypercholesterolemia treatments: guidelines and new therapies. <em>Atherosclerosis</em> 2018;277:483-492.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.atherosclerosis.2018.06.859" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30270089/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000445908000072" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Familial+hypercholesterolemia+treatments%3A+guidelines+and+new+therapies.&amp;publication_year=2018&amp;journal=Atherosclerosis&amp;pages=483-492&amp;doi=10.1016%2Fj.atherosclerosis.2018.06.859&amp;pmid=30270089" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="r28" class="citations"><div class="citation"><div class="citation-content">Rosenson RS, Baker S, Banach M, et al. Optimizing cholesterol treatment in patients with muscle complaints. <em>J Am Coll Cardiol</em> 2017;70:1290-1301.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jacc.2017.07.752" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28859793/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000408453600012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Optimizing+cholesterol+treatment+in+patients+with+muscle+complaints.&amp;publication_year=2017&amp;journal=J+Am+Coll+Cardiol&amp;pages=1290-1301&amp;doi=10.1016%2Fj.jacc.2017.07.752&amp;pmid=28859793" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="r29" class="citations"><div class="citation"><div class="citation-content">Catapano AL, Lee LV, Louie MJ, Thompson D, Bergeron J, Krempf M. Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trials. <em>Sci Rep</em> 2017;7:45788-45788.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/srep45788" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28374849/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000398149800001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+of+alirocumab+according+to+background+statin+type+and+dose%3A+pooled+analysis+of+8+ODYSSEY+Phase+3+clinical+trials.&amp;publication_year=2017&amp;journal=Sci+Rep&amp;pages=45788-45788&amp;doi=10.1038%2Fsrep45788&amp;pmid=28374849" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="r30" class="citations"><div class="citation"><div class="citation-content">Rosenson RS, Hegele RA, Koenig W. Cholesterol-lowering agents. <em>Circ Res</em> 2019;124:364-385.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1161/CIRCRESAHA.118.313238" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30702994/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000457466300002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Cholesterol-lowering+agents.&amp;publication_year=2019&amp;journal=Circ+Res&amp;pages=364-385&amp;doi=10.1161%2FCIRCRESAHA.118.313238&amp;pmid=30702994" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="r31" class="citations"><div class="citation"><div class="citation-content">Guedeney P, Giustino G, Sorrentino S, et al. Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. <em>Eur Heart J</em> 2019 July 3 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/eurheartj/ehz746.0332" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31270529/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000507313002927" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+alirocumab+and+evolocumab%3A+a+systematic+review+and+meta-analysis+of+randomized+controlled+trials.&amp;publication_year=2019&amp;journal=Eur+Heart+J&amp;doi=10.1093%2Feurheartj%2Fehz746.0332&amp;pmid=31270529" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="r32" class="citations"><div class="citation"><div class="citation-content">Reeskamp LF, Tromp TR, Stroes ESG. The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease? <em>Curr Opin Lipidol</em> 2020;31:140-146.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r33"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/MOL.0000000000000679" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32324598/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000561384000005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+next+generation+of+triglyceride-lowering+drugs%3A+will+reducing+apolipoprotein+C-III+or+angiopoietin+like+protein+3+reduce+cardiovascular+disease%3F&amp;publication_year=2020&amp;journal=Curr+Opin+Lipidol&amp;pages=140-146&amp;doi=10.1097%2FMOL.0000000000000679&amp;pmid=32324598" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="r33" class="citations"><div class="citation"><div class="citation-content">Lincoff AM, Nicholls SJ, Riesmeyer JS, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. <em>N Engl J Med</em> 2017;376:1933-1942.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r33"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_34_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2031049&amp;key=10.1056%2FNEJMoa1609581&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28514624/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000401407500007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Evacetrapib+and+cardiovascular+outcomes+in+high-risk+vascular+disease.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=1933-1942&amp;doi=10.1056%2FNEJMoa1609581&amp;pmid=28514624" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="r34" class="citations"><div class="citation"><div class="citation-content">Ference BA, Kastelein JJP, Ray KK, et al. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. <em>JAMA</em> 2019;321:364-373.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r34"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2018.20045" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30694319/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000457130400022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Association+of+triglyceride-lowering+LPL+variants+and+LDL-C-lowering+LDLR+variants+with+risk+of+coronary+heart+disease.&amp;publication_year=2019&amp;journal=JAMA&amp;pages=364-373&amp;doi=10.1001%2Fjama.2018.20045&amp;pmid=30694319" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="r35" class="citations"><div class="citation"><div class="citation-content">Toth PP, Granowitz C, Hull M, Liassou D, Anderson A, Philip S. High triglycerides are associated with increased cardiovascular events, medical costs, and resource use: a real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk. <em>J Am Heart Assoc</em> 2018;7(15):e008740-e008740.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1161/JAHA.118.008740" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30371242/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000452701900009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=High+triglycerides+are+associated+with+increased+cardiovascular+events%2C+medical+costs%2C+and+resource+use%3A+a+real-world+administrative+claims+analysis+of+statin-treated+patients+with+high+residual+cardiovascular+risk.&amp;publication_year=2018&amp;journal=J+Am+Heart+Assoc&amp;pages=e008740-e008740&amp;doi=10.1161%2FJAHA.118.008740&amp;pmid=30371242" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">36.</div><div id="r36" class="citations"><div class="citation"><div class="citation-content">Tavori H, Giunzioni I, Fazio S. PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9. <em>Curr Opin Endocrinol Diabetes Obes</em> 2015;22:126-132.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r36"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/MED.0000000000000137" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25692926/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=PCSK9+inhibition+to+reduce+cardiovascular+disease+risk%3A+recent+findings+from+the+biology+of+PCSK9.&amp;publication_year=2015&amp;journal=Curr+Opin+Endocrinol+Diabetes+Obes&amp;pages=126-132&amp;doi=10.1097%2FMED.0000000000000137&amp;pmid=25692926" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">37.</div><div id="r37" class="citations"><div class="citation"><div class="citation-content">Bittner B, Richter W, Schmidt J. Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. <em>BioDrugs</em> 2018;32:425-440.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r37" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s40259-018-0295-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30043229/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000446665700004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Subcutaneous+administration+of+biotherapeutics%3A+an+overview+of+current+challenges+and+opportunities.&amp;publication_year=2018&amp;journal=BioDrugs&amp;pages=425-440&amp;doi=10.1007%2Fs40259-018-0295-0&amp;pmid=30043229" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r37" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r38" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] of work productivity and personal time. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r37-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] health care costs related to drug delivery. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">38.</div><div id="r38" class="citations"><div class="citation"><div class="citation-content">Johnson ML, Braiteh F, Grilley-Olson JE, et al. Assessment of subcutaneous vs intravenous administration of anti-PD-1 antibody PF-06801591 in patients with advanced solid tumors: a phase 1 dose-escalation trial. <em>JAMA Oncol</em> 2019;5:999-1007.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r38"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jamaoncol.2019.0836" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31145415/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000481511600016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Assessment+of+subcutaneous+vs+intravenous+administration+of+anti-PD-1+antibody+PF-06801591+in+patients+with+advanced+solid+tumors%3A+a+phase+1+dose-escalation+trial.&amp;publication_year=2019&amp;journal=JAMA+Oncol&amp;pages=999-1007&amp;doi=10.1001%2Fjamaoncol.2019.0836&amp;pmid=31145415" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">39.</div><div id="r39" class="citations"><div class="citation"><div class="citation-content">Ginsberg HN, Rader DJ, Raal FJ, et al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg/dl or higher. <em>Cardiovasc Drugs Ther</em> 2016;30:473-483.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r40"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s10557-016-6685-y" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27618825/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000385185600006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+alirocumab+in+patients+with+heterozygous+familial+hypercholesterolemia+and+LDL-C+of+160+mg%2Fdl+or+higher.&amp;publication_year=2016&amp;journal=Cardiovasc+Drugs+Ther&amp;pages=473-483&amp;doi=10.1007%2Fs10557-016-6685-y&amp;pmid=27618825" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">40.</div><div id="r40" class="citations"><div class="citation"><div class="citation-content">Santos RD, Stein EA, Hovingh GK, et al. Long-term evolocumab in patients with familial hypercholesterolemia. <em>J Am Coll Cardiol</em> 2020;75:565-574.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r40"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jacc.2019.12.020" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32057369/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000512903000001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Long-term+evolocumab+in+patients+with+familial+hypercholesterolemia.&amp;publication_year=2020&amp;journal=J+Am+Coll+Cardiol&amp;pages=565-574&amp;doi=10.1016%2Fj.jacc.2019.12.020&amp;pmid=32057369" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/383/24"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">383</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">24</span></span> • <span property="datePublished">December 10, 2020</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">2307</span>-<span property="pageEnd">2319</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2020 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section data-translation="YXQYoa2031049" class="core-component-translation"><h4>Translation</h4><div role="paragraph"><a target="_blank" href="https://nejmqianyan.cn/article/YXQYoa2031049?sg=AbW1N">Chinese Translation 中文翻译</a></div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: November 15, 2020</div><div><b class="core-label">Published in issue</b>: December 10, 2020</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/lipids" alt="View article keyword Lipids" data-interactiontype="article_recirculation_click">Lipids</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/prevention" alt="View article keyword Prevention" data-interactiontype="article_recirculation_click">Prevention</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Robert S.</span> <span property="familyName">Rosenson</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Lesley J.</span> <span property="familyName">Burgess</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Christoph F.</span> <span property="familyName">Ebenbichler</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Seth J.</span> <span property="familyName">Baum</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Erik S.G.</span> <span property="familyName">Stroes</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Shazia</span> <span property="familyName">Ali</span>, <span property="honorificSuffix">Pharm.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Nagwa</span> <span property="familyName">Khilla</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Robert</span> <span property="familyName">Hamlin</span>, <span property="honorificSuffix">B.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Robert</span> <span property="familyName">Pordy</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Yuping</span> <span property="familyName">Dong</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Vladimir</span> <span property="familyName">Son</span>, <span property="honorificSuffix">Ph.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Daniel</span> <span property="familyName">Gaudet</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the Icahn School of Medicine at Mount Sinai, New York (R.S.R.), and Regeneron Pharmaceuticals, Tarrytown (S.A., N.K., R.H., R.P., Y.D., V.S.) — both in New York; TREAD Research, Cardiology Unit, Department of Internal Medicine and Tygerberg Hospital, Parow, South Africa (L.J.B.); the Department of Internal Medicine I, Medical University Innsbruck, Innsbruck, Austria (C.F.E.); Excel Medical Clinical Trials, Department of Integrated Medical Sciences, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton (S.J.B.); the Department of Vascular Medicine, Academic Medical Center, Amsterdam (E.S.G.S.); and the Clinical Lipidology and Rare Lipid Disorders Unit, Department of Medicine, Université de Montréal Community Gene Medicine Center, Montreal, and ECOGENE-21 Clinical and Translational Research Center, Chicoutimi, QC — both in Canada (D.G.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. Rosenson at Icahn School of Medicine at Mount Sinai, 1425 Madison Ave., MC Level, New York, NY 10029.</div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">230</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2031049" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="788e2176-6479-d5a6-e524-4eb1c5c8fdeb"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=94315677" style="display:inline-block;">
                <img alt="Article has an altmetric score of 273" src="https://badges.altmetric.com/?size=320&amp;score=273&amp;types=mabcttfd" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=94315677">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_788e2176-6479-d5a6-e524-4eb1c5c8fdeb" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=94315677&amp;tab=news">
          Picked up by <b>26</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=94315677&amp;tab=blogs">
          Blogged by <b>3</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #9f79f2;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=94315677&amp;tab=policy-documents">
          Referenced in <b>1</b> policy sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=94315677&amp;tab=twitter">
          Posted by <b>108</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=94315677&amp;tab=patents">
          Referenced in <b>4</b> patents
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=94315677&amp;tab=facebook">
          On <b>2</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #A1E3E4;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=94315677&amp;tab=guidelines">
          Referenced in <b>1</b> clinical guideline sources
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>168</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d65b3a97347810-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2031049"> <input type="hidden" name="downloadFileName" value="csp_383_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.383.issue-24%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2031049%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="230" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Fatemeh Vahdat-Lasemi, </li><li class="list-inline-item cited-by__entry__author">Leila Farhoudi, </li><li class="list-inline-item cited-by__entry__author">Seyedeh Maryam Hosseinikhah, </li><li class="list-inline-item cited-by__entry__author">Raul D. Santos, </li><li class="list-inline-item cited-by__entry__author">Amirhossein Sahebkar, </li></ul><span class="cited-by__entry__title">Angiopoietin-like protein inhibitors: Promising agents for the treatment of familial hypercholesterolemia and atherogenic dyslipidemia, </span><span class="cited-by__entry__series-title">Atherosclerosis, </span><span class="cited-by__entry__volume"><strong>405</strong>, </span><span class="cited-by__entry__page-range">(119235), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.atherosclerosis.2025.119235" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.atherosclerosis.2025.119235</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.atherosclerosis.2025.119235" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Seyedmohammad Saadatagah, </li><li class="list-inline-item cited-by__entry__author">Miriam Larouche, </li><li class="list-inline-item cited-by__entry__author">Mohammadreza Naderian, </li><li class="list-inline-item cited-by__entry__author">Vijay Nambi, </li><li class="list-inline-item cited-by__entry__author">Diane Brisson, </li><li class="list-inline-item cited-by__entry__author">Iftikhar J. Kullo, </li><li class="list-inline-item cited-by__entry__author">P Barton Duell, </li><li class="list-inline-item cited-by__entry__author">Erin D. Michos, </li><li class="list-inline-item cited-by__entry__author">Michael D. Shapiro, </li><li class="list-inline-item cited-by__entry__author">Gerald F. Watts, </li><li class="list-inline-item cited-by__entry__author">Daniel Gaudet, </li><li class="list-inline-item cited-by__entry__author">Christie M. Ballantyne, </li></ul><span class="cited-by__entry__title">Recognition and management of persistent chylomicronemia: A joint expert clinical consensus by the National Lipid Association and the American Society for Preventive Cardiology, </span><span class="cited-by__entry__series-title">American Journal of Preventive Cardiology, </span><span class="cited-by__entry__volume"><strong>22</strong>, </span><span class="cited-by__entry__page-range">(100978), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.ajpc.2025.100978" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.ajpc.2025.100978</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.ajpc.2025.100978" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Michael J. Wilkinson, </li><li class="list-inline-item cited-by__entry__author">Priyesha Bijlani, </li><li class="list-inline-item cited-by__entry__author">Michael H. Davidson, </li><li class="list-inline-item cited-by__entry__author">P. Barton Duell, </li><li class="list-inline-item cited-by__entry__author">Mary Horan, </li><li class="list-inline-item cited-by__entry__author">Mary J. Malloy, </li><li class="list-inline-item cited-by__entry__author">Ron S. Newfield, </li><li class="list-inline-item cited-by__entry__author">Pallavi Pradeep, </li><li class="list-inline-item cited-by__entry__author">Prediman K. Shah, </li><li class="list-inline-item cited-by__entry__author">Eveline O. Stock, </li><li class="list-inline-item cited-by__entry__author">Bruce A. Warden, </li><li class="list-inline-item cited-by__entry__author">Matthew K. Ito, </li></ul><span class="cited-by__entry__title">Real-World Effectiveness and Safety of Evinacumab in Children and Adults With Homozygous Familial Hypercholesterolemia: A Multisite US Perspective, </span><span class="cited-by__entry__series-title">Arteriosclerosis, Thrombosis, and Vascular Biology, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1161/ATVBAHA.124.322364" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1161/ATVBAHA.124.322364</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1161/ATVBAHA.124.322364" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Dan Song, </li><li class="list-inline-item cited-by__entry__author">Yang Li, </li><li class="list-inline-item cited-by__entry__author">Ling-Ling Yang, </li><li class="list-inline-item cited-by__entry__author">Ya-Xi Luo, </li><li class="list-inline-item cited-by__entry__author">Xiu-Qing Yao, </li></ul><span class="cited-by__entry__title">Bridging systemic metabolic dysfunction and Alzheimer’s disease: the liver interface, </span><span class="cited-by__entry__series-title">Molecular Neurodegeneration, </span><span class="cited-by__entry__volume"><strong>20</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1186/s13024-025-00849-6" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1186/s13024-025-00849-6</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1186/s13024-025-00849-6" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Xiaojie Xie, </li><li class="list-inline-item cited-by__entry__author">Xiaoxia Shi, </li><li class="list-inline-item cited-by__entry__author">Yuming Zhang, </li><li class="list-inline-item cited-by__entry__author">Shuhong Su, </li><li class="list-inline-item cited-by__entry__author">Chenyan Jiang, </li><li class="list-inline-item cited-by__entry__author">Liu Miao, </li><li class="list-inline-item cited-by__entry__author">Junkui Wang, </li><li class="list-inline-item cited-by__entry__author">Daoquan Peng, </li><li class="list-inline-item cited-by__entry__author">Lingchun Lv, </li><li class="list-inline-item cited-by__entry__author">Xiaohong Chai, </li><li class="list-inline-item cited-by__entry__author">Suxin Luo, </li><li class="list-inline-item cited-by__entry__author">Yang Zheng, </li><li class="list-inline-item cited-by__entry__author">Shan Huang, </li><li class="list-inline-item cited-by__entry__author">Dan Zhu, </li><li class="list-inline-item cited-by__entry__author">Shangshang Liao, </li><li class="list-inline-item cited-by__entry__author">Meng Ren, </li><li class="list-inline-item cited-by__entry__author">Xiaohong Gao, </li><li class="list-inline-item cited-by__entry__author">Haibo Yang, </li><li class="list-inline-item cited-by__entry__author">Hao Zhou, </li><li class="list-inline-item cited-by__entry__author">Yuquan He, </li><li class="list-inline-item cited-by__entry__author">Yajun Han, </li><li class="list-inline-item cited-by__entry__author">Jiahong Xu, </li><li class="list-inline-item cited-by__entry__author">Lin Zhang, </li><li class="list-inline-item cited-by__entry__author">Laijing Du, </li><li class="list-inline-item cited-by__entry__author">Zhuhua Yao, </li><li class="list-inline-item cited-by__entry__author">Jianlong Sheng, </li><li class="list-inline-item cited-by__entry__author">Xiaoping Peng, </li><li class="list-inline-item cited-by__entry__author">Xiaowen Chen, </li><li class="list-inline-item cited-by__entry__author">Juxiang Li, </li><li class="list-inline-item cited-by__entry__author">Jie Mi, </li><li class="list-inline-item cited-by__entry__author">Qiang Lu, </li><li class="list-inline-item cited-by__entry__author">Hongju Wang, </li><li class="list-inline-item cited-by__entry__author">Zheng Shen, </li><li class="list-inline-item cited-by__entry__author">Zhilin Zhao, </li><li class="list-inline-item cited-by__entry__author">Feng Gao, </li><li class="list-inline-item cited-by__entry__author">Chao Lv, </li><li class="list-inline-item cited-by__entry__author">Min Zhu, </li><li class="list-inline-item cited-by__entry__author">Ying Zhu, </li><li class="list-inline-item cited-by__entry__author">Jian’an Wang, </li></ul><span class="cited-by__entry__title">Angiopoietin-Like 3 Antibody Therapy in&nbsp;Patients With Suboptimally Controlled&nbsp;Hyperlipidemia, </span><span class="cited-by__entry__series-title">Journal of the American College of Cardiology, </span><span class="cited-by__entry__volume"><strong>85</strong>, </span><span class="cited-by__entry__issue">19, </span><span class="cited-by__entry__page-range">(1821-1835), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jacc.2025.03.008" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jacc.2025.03.008</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jacc.2025.03.008" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Kausik K. Ray, </li><li class="list-inline-item cited-by__entry__author">Helle Linnebjerg, </li><li class="list-inline-item cited-by__entry__author">Laura F. Michael, </li><li class="list-inline-item cited-by__entry__author">Xi Shen, </li><li class="list-inline-item cited-by__entry__author">Xiaosu Ma, </li><li class="list-inline-item cited-by__entry__author">Shufen Lim, </li><li class="list-inline-item cited-by__entry__author">Eugene Y. Zhen, </li><li class="list-inline-item cited-by__entry__author">Henryk Dudek, </li><li class="list-inline-item cited-by__entry__author">Marc Abrams, </li><li class="list-inline-item cited-by__entry__author">Utsav Saxena, </li><li class="list-inline-item cited-by__entry__author">Anton Turanov, </li><li class="list-inline-item cited-by__entry__author">Stephen J. Nicholls, </li><li class="list-inline-item cited-by__entry__author">Giacomo Ruotolo, </li></ul><span class="cited-by__entry__title">Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early&nbsp;Human&nbsp;Studies, </span><span class="cited-by__entry__series-title">Journal of the American College of Cardiology, </span><span class="cited-by__entry__volume"><strong>85</strong>, </span><span class="cited-by__entry__issue">19, </span><span class="cited-by__entry__page-range">(1803-1818), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jacc.2025.03.005" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jacc.2025.03.005</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jacc.2025.03.005" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Ask T. Nordestgaard, </li><li class="list-inline-item cited-by__entry__author">Anne Tybjærg-Hansen, </li><li class="list-inline-item cited-by__entry__author">Hank Mansbach, </li><li class="list-inline-item cited-by__entry__author">Sander Kersten, </li><li class="list-inline-item cited-by__entry__author">Børge G. Nordestgaard, </li><li class="list-inline-item cited-by__entry__author">Robert S. Rosenson, </li></ul><span class="cited-by__entry__title">Target Populations for Novel Triglyceride-Lowering Therapies, </span><span class="cited-by__entry__series-title">Journal of the American College of Cardiology, </span><span class="cited-by__entry__volume"><strong>85</strong>, </span><span class="cited-by__entry__issue">19, </span><span class="cited-by__entry__page-range">(1876-1897), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jacc.2025.02.035" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jacc.2025.02.035</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jacc.2025.02.035" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Liangxing Tu, </li><li class="list-inline-item cited-by__entry__author">Zijian Zou, </li><li class="list-inline-item cited-by__entry__author">Ye Yang, </li><li class="list-inline-item cited-by__entry__author">Siying Wang, </li><li class="list-inline-item cited-by__entry__author">Banghuai Xing, </li><li class="list-inline-item cited-by__entry__author">Jianfang Feng, </li><li class="list-inline-item cited-by__entry__author">Yi Jin, </li><li class="list-inline-item cited-by__entry__author">Meng Cheng, </li></ul><span class="cited-by__entry__title">Targeted drug delivery systems for atherosclerosis, </span><span class="cited-by__entry__series-title">Journal of Nanobiotechnology, </span><span class="cited-by__entry__volume"><strong>23</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1186/s12951-025-03384-0" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1186/s12951-025-03384-0</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1186/s12951-025-03384-0" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Anders B. Wulff, </li><li class="list-inline-item cited-by__entry__author">Børge G. Nordestgaard, </li></ul><span class="cited-by__entry__title">Genetics of remnant cholesterol, </span><span class="cited-by__entry__series-title">Current Opinion in Lipidology, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1097/MOL.0000000000000991" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1097/MOL.0000000000000991</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1097/MOL.0000000000000991" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Daniele Tramontano, </li><li class="list-inline-item cited-by__entry__author">Simone Bini, </li><li class="list-inline-item cited-by__entry__author">Carlo Maiorca, </li><li class="list-inline-item cited-by__entry__author">Alessia Di Costanzo, </li><li class="list-inline-item cited-by__entry__author">Martina Carosi, </li><li class="list-inline-item cited-by__entry__author">Jacopo Castellese, </li><li class="list-inline-item cited-by__entry__author">Ina Arizaj, </li><li class="list-inline-item cited-by__entry__author">Daniela Commodari, </li><li class="list-inline-item cited-by__entry__author">Stella Covino, </li><li class="list-inline-item cited-by__entry__author">Giorgia Sansone, </li><li class="list-inline-item cited-by__entry__author">Ilenia Minicocci, </li><li class="list-inline-item cited-by__entry__author">Marcello Arca, </li><li class="list-inline-item cited-by__entry__author">Laura D’Erasmo, </li></ul><span class="cited-by__entry__title">Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions, </span><span class="cited-by__entry__series-title">Drugs, </span><span class="cited-by__entry__volume"><strong>85</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(755-775), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1007/s40265-025-02158-0" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1007/s40265-025-02158-0</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1007/s40265-025-02158-0" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.383.issue-24%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2031049%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2031049" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2031049" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2031049.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2031049_f1.jpg"><img src="/cms/10.1056/NEJMoa2031049/asset/5c7f9b97-f91e-40c3-bff7-98a3125bf75e/assets/images/large/nejmoa2031049_f1.jpg" height="1394" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Least-Squares Mean Percent Change from Baseline in the Calculated Low-Density Lipoprotein Cholesterol Level at Week 16.</div><div class="notes"><div role="doc-footnote">The least-squares mean and standard errors are taken from a mixed-effect model with a repeated-measures approach, with the categorical fixed effects of treatment (evinacumab or placebo), randomization strata (receipt of a high-intensity statin [yes or no] and presence of heterozygous familial hypercholesterolemia [yes or no]), time point up to week 16, treatment-by-time point interaction, and strata-by-time point interaction, as well as continuous fixed covariates of the calculated low-density lipoprotein (LDL) cholesterol level at baseline and baseline LDL cholesterol level-by-time point interaction. 𝙸 bars indicate standard errors.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2031049_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2031049_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2031049/asset/9fbcb9ec-73d2-4bd8-a8f5-f92bd765de62/assets/images/large/nejmoa2031049_t1.jpg" height="3081" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders" colspan="3"><span>Subcutaneous Evinacumab</span></th><th class="txxx-borders">Subcutaneous Placebo, Weekly (N=39)</th><th class="txxr-borders">Total (N=160)</th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">450 mg Weekly (N=40)</th><th class="xxxx-borders">300 mg Weekly (N=42)</th><th class="xxxx-borders">300 mg Every 2 Wk (N=39)</th><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Age — yr</td><td class="xxxx-borders shading">54.5±15.1</td><td class="xxxx-borders shading">54.0±12.2</td><td class="xxxx-borders shading">55.0±13.0</td><td class="xxxx-borders shading">52.4±12.7</td><td class="xxxr-borders shading">54.0±13.2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders">29 (72)</td><td class="xxxx-borders">23 (55)</td><td class="xxxx-borders">21 (54)</td><td class="xxxx-borders">27 (69)</td><td class="xxxr-borders">100 (62)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Race — no. (%)<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">White</td><td class="xxxx-borders">38 (95)</td><td class="xxxx-borders">39 (93)</td><td class="xxxx-borders">34 (87)</td><td class="xxxx-borders">34 (87)</td><td class="xxxr-borders">145 (91)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Black</td><td class="xxxx-borders shading">1 (2)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">3 (8)</td><td class="xxxr-borders shading">4 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Asian</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">1 (3)</td><td class="xxxr-borders">3 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Other</td><td class="xxxx-borders shading">1 (2)</td><td class="xxxx-borders shading">1 (2)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxr-borders shading">3 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Not reported</td><td class="xxxx-borders">0</td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">3 (8)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">5 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Body-mass index<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">27.9±4.4</td><td class="xxxx-borders shading">29.3±4.9</td><td class="xxxx-borders shading">28.0±4.4</td><td class="xxxx-borders shading">29.1±5.2</td><td class="xxxr-borders shading">28.6±4.7</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Heterozygous familial hypercholesterolemia status — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Present</td><td class="xxxx-borders shading">29 (72)</td><td class="xxxx-borders shading">30 (71)</td><td class="xxxx-borders shading">29 (74)</td><td class="xxxx-borders shading">28 (72)</td><td class="xxxr-borders shading">116 (72)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Diagnosed with genotyping</td><td class="xxxx-borders">13 (32)</td><td class="xxxx-borders">16 (38)</td><td class="xxxx-borders">11 (28)</td><td class="xxxx-borders">9 (23)</td><td class="xxxr-borders">49 (31)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Diagnosed with clinical criteria</td><td class="xxxx-borders shading">16 (40)</td><td class="xxxx-borders shading">14 (33)</td><td class="xxxx-borders shading">18 (46)</td><td class="xxxx-borders shading">19 (49)</td><td class="xxxr-borders shading">67 (42)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Absent</td><td class="xxxx-borders">11 (28)</td><td class="xxxx-borders">12 (29)</td><td class="xxxx-borders">10 (26)</td><td class="xxxx-borders">11 (28)</td><td class="xxxr-borders">44 (28)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Calculated LDL cholesterol — mg/dl</td><td class="xxxx-borders shading">146.3±84.6</td><td class="xxxx-borders shading">159.1±73.0</td><td class="xxxx-borders shading">136.2±70.2</td><td class="xxxx-borders shading">157.8±92.4</td><td class="xxxr-borders shading">150.0±80.2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Apolipoprotein B — mg/dl</td><td class="xxxx-borders">112.4±43.1</td><td class="xxxx-borders">123.2±42.1</td><td class="xxxx-borders">107.8±43.8</td><td class="xxxx-borders">120.6±51.1</td><td class="xxxr-borders">116.1±45.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">HDL cholesterol — mg/dl</td><td class="xxxx-borders shading">52.5±13.8</td><td class="xxxx-borders shading">57.0±22.9</td><td class="xxxx-borders shading">51.7±15.5</td><td class="xxxx-borders shading">56.2±16.7</td><td class="xxxr-borders shading">54.4±17.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Non-HDL cholesterol — mg/dl</td><td class="xxxx-borders">173.0±84.8</td><td class="xxxx-borders">185.1±74.8</td><td class="xxxx-borders">165.3±71.2</td><td class="xxxx-borders">183.9±92.8</td><td class="xxxr-borders">176.9±80.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Total cholesterol — mg/dl</td><td class="xxxx-borders shading">225.5±86.2</td><td class="xxxx-borders shading">242.2±77.3</td><td class="xxxx-borders shading">217.0±68.8</td><td class="xxxx-borders shading">240.1±91.9</td><td class="xxxr-borders shading">231.4±81.4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Median fasting triglycerides (IQR) — mg/dl</td><td class="xxxx-borders">109.5 (82.0–183.5)</td><td class="xxxx-borders">118.5 (83.0–177.0)</td><td class="xxxx-borders">128.0 (87.0–167.0)</td><td class="xxxx-borders">112.0 (85.0–176.0)</td><td class="xxxr-borders">114.5 (85.5–176.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Median lipoprotein(a) (IQR) — nmol/liter</td><td class="xxxx-borders shading">24.5 (15.5–97.5)</td><td class="xxxx-borders shading">81.5 (21.0–231.0)</td><td class="xxxx-borders shading">60.0 (16.0–128.0)</td><td class="xxxx-borders shading">48.0 (21.0–170.0)</td><td class="xxxr-borders shading">46.5 (17.0–154.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Coronary heart disease — no. (%)</td><td class="xxxx-borders">22 (55)</td><td class="xxxx-borders">21 (50)</td><td class="xxxx-borders">22 (56)</td><td class="xxxx-borders">21 (54)</td><td class="xxxr-borders">86 (54)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Acute myocardial infarction</td><td class="xxxx-borders shading">7 (18)</td><td class="xxxx-borders shading">13 (31)</td><td class="xxxx-borders shading">9 (23)</td><td class="xxxx-borders shading">9 (23)</td><td class="xxxr-borders shading">38 (24)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Silent myocardial infarction</td><td class="xxxx-borders">1 (2)</td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">3 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Chronic stable or unstable angina</td><td class="xxxx-borders shading">14 (35)</td><td class="xxxx-borders shading">9 (21)</td><td class="xxxx-borders shading">16 (41)</td><td class="xxxx-borders shading">16 (41)</td><td class="xxxr-borders shading">55 (34)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Coronary revascularization procedure</td><td class="xxxx-borders">17 (42)</td><td class="xxxx-borders">18 (43)</td><td class="xxxx-borders">17 (44)</td><td class="xxxx-borders">13 (33)</td><td class="xxxr-borders">65 (41)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Risk equivalents of coronary heart disease — no. (%)</td><td class="xxxx-borders shading">9 (22)</td><td class="xxxx-borders shading">7 (17)</td><td class="xxxx-borders shading">8 (20)</td><td class="xxxx-borders shading">7 (18)</td><td class="xxxr-borders shading">31 (19)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Peripheral arterial disease</td><td class="xxxx-borders">4 (10)</td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">7 (18)</td><td class="xxxx-borders">4 (10)</td><td class="xxxr-borders">17 (11)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Ischemic stroke</td><td class="xxxx-borders shading">5 (12)</td><td class="xxxx-borders shading">2 (5)</td><td class="xxxx-borders shading">2 (5)</td><td class="xxxx-borders shading">2 (5)</td><td class="xxxr-borders shading">11 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Chronic kidney disease</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (3)</td><td class="xxxr-borders">1 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Known history of type 1 or 2 diabetes mellitus and ≥2 additional risk factors<a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">3 (8)</td><td class="xxxx-borders shading">3 (7)</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxr-borders shading">8 (5)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Lipid-lowering therapy — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Any statin</td><td class="xxxx-borders shading">24 (60)</td><td class="xxxx-borders shading">24 (57)</td><td class="xxxx-borders shading">24 (62)</td><td class="xxxx-borders shading">27 (69)</td><td class="xxxr-borders shading">99 (62)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">High-intensity statin<a href="#core-t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">17 (42)</td><td class="xxxx-borders">21 (50)</td><td class="xxxx-borders">14 (36)</td><td class="xxxx-borders">19 (49)</td><td class="xxxr-borders">71 (44)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Ezetimibe</td><td class="xxxx-borders shading">7 (18)</td><td class="xxxx-borders shading">15 (36)</td><td class="xxxx-borders shading">12 (31)</td><td class="xxxx-borders shading">14 (36)</td><td class="xxxr-borders shading">48 (30)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging13" data-xml-align="left">PCSK9 inhibitor</td><td class="xbxx-borders">40 (100)</td><td class="xbxx-borders">42 (100)</td><td class="xbxx-borders">39 (100)</td><td class="xbxx-borders">39 (100)</td><td class="xbxr-borders">160 (100)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Plus–minus values are means ±SD. Data are shown for the intention-to-treat population. Percentages may not total 100 because of rounding. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. To convert the values for triglycerides to millimoles per liter, multiply by 0.01129. HDL denotes high-density lipoprotein, IQR interquartile range, LDL low-density lipoprotein, and PCSK9 proprotein convertase subtilisin–kexin type 9.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Race was reported by the patient.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">The body-mass index is the weight in kilograms divided by the square of the height in meters.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">Risk factors include a history of an ankle–brachial index of 0.9 or lower, a history of hypertension, a history of microalbuminuria or macroalbuminuria, a history of proliferative diabetic retinopathy, and a known family history of coronary heart disease.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t1fn5" role="paragraph" data-to-manipulate="true">High-intensity statin was defined as rosuvastatin at a dose of 20 mg or 40 mg daily, atorvastatin at a dose of 40 mg or 80 mg daily, or simvastatin at a dose of 80 mg daily (if the patient had been receiving this regimen for &gt;1 year).</div></div></div></figcaption></a><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients in the Subcutaneous-Treatment Groups.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2031049_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2031049_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2031049/asset/2884dab0-ac0d-47a3-9162-69ce39e956a5/assets/images/large/nejmoa2031049_t2.jpg" height="2859" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders" colspan="2"><span>Intravenous Evinacumab</span></th><th class="txxx-borders">Intravenous Placebo, Every 4 Wk<br>(N=33)</th><th class="txxr-borders">Total <br>(N=106)</th></tr></thead><tbody><tr class="head2" data-xml-align="center" data-type="row head2" data-xml-valign="bottom"><td class="xxlx-borders hanging03">&nbsp;</td><td class="xxxx-borders">15 mg/kg Every 4 Wk<br>(N=38)</td><td class="xxxx-borders">5 mg/kg Every 4 Wk<br>(N=35)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Age — yr</td><td class="xxxx-borders shading">52.1±12.1</td><td class="xxxx-borders shading">55.7±9.6</td><td class="xxxx-borders shading">56.2±10.9</td><td class="xxxr-borders shading">54.6±11.0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders">19 (50)</td><td class="xxxx-borders">22 (63)</td><td class="xxxx-borders">18 (55)</td><td class="xxxr-borders">59 (56)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Race — no. (%)<a href="#core-t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">White</td><td class="xxxx-borders">35 (92)</td><td class="xxxx-borders">32 (91)</td><td class="xxxx-borders">27 (82)</td><td class="xxxr-borders">94 (89)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Black</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (6)</td><td class="xxxr-borders shading">2 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Asian</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">1 (3)</td><td class="xxxr-borders">2 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Other</td><td class="xxxx-borders shading">3 (8)</td><td class="xxxx-borders shading">2 (6)</td><td class="xxxx-borders shading">3 (9)</td><td class="xxxr-borders shading">8 (8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Body-mass index<a href="#core-t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">29.3±4.9</td><td class="xxxx-borders">28.8±4.6</td><td class="xxxx-borders">28.8±5.2</td><td class="xxxr-borders">29.0±4.9</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Heterozygous familial hypercholesterolemia status — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Present</td><td class="xxxx-borders">31 (82)</td><td class="xxxx-borders">29 (83)</td><td class="xxxx-borders">26 (79)</td><td class="xxxr-borders">86 (81)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Diagnosed with genotyping</td><td class="xxxx-borders shading">10 (26)</td><td class="xxxx-borders shading">11 (31)</td><td class="xxxx-borders shading">11 (33)</td><td class="xxxr-borders shading">32 (30)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Diagnosed with clinical criteria</td><td class="xxxx-borders">21 (55)</td><td class="xxxx-borders">18 (51)</td><td class="xxxx-borders">15 (45)</td><td class="xxxr-borders">54 (51)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Absent</td><td class="xxxx-borders shading">7 (18)</td><td class="xxxx-borders shading">6 (17)</td><td class="xxxx-borders shading">7 (21)</td><td class="xxxr-borders shading">20 (19)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Calculated LDL cholesterol — mg/dl</td><td class="xxxx-borders">143.1±54.4</td><td class="xxxx-borders">146.0±61.0</td><td class="xxxx-borders">144.5±46.6</td><td class="xxxr-borders">144.5±54.0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Apolipoprotein B — mg/dl</td><td class="xxxx-borders shading">112.6±32.4</td><td class="xxxx-borders shading">113.4±33.8</td><td class="xxxx-borders shading">116.7±27.0</td><td class="xxxr-borders shading">114.1±31.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">HDL cholesterol — mg/dl</td><td class="xxxx-borders">51.5±17.4</td><td class="xxxx-borders">58.2±16.8</td><td class="xxxx-borders">55.4±18.0</td><td class="xxxr-borders">54.9±17.4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Non-HDL cholesterol — mg/dl</td><td class="xxxx-borders shading">169.4±54.2</td><td class="xxxx-borders shading">170.6±61.5</td><td class="xxxx-borders shading">176.2±48.0</td><td class="xxxr-borders shading">171.9±54.5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Total cholesterol — mg/dl</td><td class="xxxx-borders">220.9±56.8</td><td class="xxxx-borders">228.8±60.2</td><td class="xxxx-borders">231.6±50.4</td><td class="xxxr-borders">226.8±55.7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Median fasting triglycerides (IQR) — mg/dl</td><td class="xxxx-borders shading">126.5 (89.0–166.0)</td><td class="xxxx-borders shading">102.0 (86.0–156.0)</td><td class="xxxx-borders shading">147.0 (104.0–200.0)</td><td class="xxxr-borders shading">122.0 (92.0–171.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Median lipoprotein(a) (IQR) — nmol/liter</td><td class="xxxx-borders">34.0 (15.0–157.0)</td><td class="xxxx-borders">27.0 (18.0–80.0)</td><td class="xxxx-borders">33.0 (16.0–154.0)</td><td class="xxxr-borders">31.0 (17.0–127.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Coronary heart disease — no. (%)</td><td class="xxxx-borders shading">21 (55)</td><td class="xxxx-borders shading">20 (57)</td><td class="xxxx-borders shading">25 (76)</td><td class="xxxr-borders shading">66 (62)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Acute myocardial infarction</td><td class="xxxx-borders">13 (34)</td><td class="xxxx-borders">10 (29)</td><td class="xxxx-borders">14 (42)</td><td class="xxxr-borders">37 (35)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Silent myocardial infarction</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Chronic stable or unstable angina</td><td class="xxxx-borders">13 (34)</td><td class="xxxx-borders">16 (46)</td><td class="xxxx-borders">16 (48)</td><td class="xxxr-borders">45 (42)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Coronary revascularization procedure</td><td class="xxxx-borders shading">19 (50)</td><td class="xxxx-borders shading">15 (43)</td><td class="xxxx-borders shading">20 (61)</td><td class="xxxr-borders shading">54 (51)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Risk equivalents of coronary heart disease — no. (%)</td><td class="xxxx-borders">10 (26)</td><td class="xxxx-borders">4 (11)</td><td class="xxxx-borders">7 (21)</td><td class="xxxr-borders">21 (20)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Peripheral arterial disease</td><td class="xxxx-borders shading">8 (21)</td><td class="xxxx-borders shading">2 (6)</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxr-borders shading">11 (10)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Ischemic stroke</td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">1 (3)</td><td class="xxxx-borders">2 (6)</td><td class="xxxr-borders">5 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Chronic kidney disease</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxr-borders shading">1 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Known history of type 1 or 2 diabetes mellitus and ≥2 additional risk factors<a href="#core-t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">2 (5)</td><td class="xxxx-borders">2 (6)</td><td class="xxxx-borders">4 (12)</td><td class="xxxr-borders">8 (8)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Lipid-lowering therapy — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Any statin</td><td class="xxxx-borders">33 (87)</td><td class="xxxx-borders">27 (77)</td><td class="xxxx-borders">28 (85)</td><td class="xxxr-borders">88 (83)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">High-intensity statin<a href="#core-t2fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">23 (61)</td><td class="xxxx-borders shading">17 (49)</td><td class="xxxx-borders shading">15 (45)</td><td class="xxxr-borders shading">55 (52)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Ezetimibe</td><td class="xxxx-borders">13 (34)</td><td class="xxxx-borders">15 (43)</td><td class="xxxx-borders">12 (36)</td><td class="xxxr-borders">40 (38)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging13 shading" data-xml-align="left">PCSK9 inhibitor</td><td class="xbxx-borders shading">37 (97)</td><td class="xbxx-borders shading">33 (94)</td><td class="xbxx-borders shading">32 (97)</td><td class="xbxr-borders shading">102 (96)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">Plus–minus values are means ±SD. Data are shown for the intention-to-treat population. Percentages may not total 100 because of rounding. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. To convert the values for triglycerides to millimoles per liter, multiply by 0.01129.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">Race was reported by the patient.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">The body-mass index is the weight in kilograms divided by the square of the height in meters.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t2fn4" role="paragraph" data-to-manipulate="true">Risk factors include a history of an ankle–brachial index of 0.9 or lower, a history of hypertension, a history of microalbuminuria or macroalbuminuria, a history of proliferative diabetic retinopathy, and a known family history of coronary heart disease.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t2fn5" role="paragraph" data-to-manipulate="true">High-intensity statin was defined as rosuvastatin at a dose of 20 mg or 40 mg daily, atorvastatin at a dose of 40 mg or 80 mg daily, or simvastatin at a dose of 80 mg daily (if the patient had been receiving this regimen for &gt;1 year).</div></div></div></figcaption></a><figcaption><div class="caption">Demographics and Clinical Characteristics of the Patients in the Intravenous-Treatment Groups.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2031049_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2031049_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2031049/asset/43607283-aa16-45b6-a24d-05b548a846c2/assets/images/large/nejmoa2031049_t3.jpg" height="1119" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Trial Group</th><th class="txxx-borders">No. of Patients</th><th class="txxx-borders">Change from Baseline in LDL Cholesterol Level</th><th class="txxx-borders">Difference vs. Placebo (95% CI)</th><th class="txxr-borders">P Value</th></tr><tr class="head3" data-type="row head3" data-xml-valign="top"><td class="xxlx-borders hanging02">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><th class="xxxx-borders">percent</th><th class="xxxx-borders">percentage points</th><td class="xxxr-borders">&nbsp;</td></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Subcutaneous regimen</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Evinacumab</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">450 mg weekly</td><td class="xxxx-borders shading">40</td><td class="xxxx-borders shading">–47.2±6.2</td><td class="xxxx-borders shading">–56.0±9.0 (–73.7 to –38.3)</td><td class="xxxr-borders shading">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">300 mg weekly</td><td class="xxxx-borders">42</td><td class="xxxx-borders">–44.0±6.3</td><td class="xxxx-borders">–52.9±9.0 (–70.7 to –35.1)</td><td class="xxxr-borders">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">300 mg every 2 wk</td><td class="xxxx-borders shading">39</td><td class="xxxx-borders shading">–29.7±6.4</td><td class="xxxx-borders shading">–38.5±9.1 (–56.5 to –20.6)</td><td class="xxxr-borders shading">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Placebo, weekly</td><td class="xxxx-borders">39</td><td class="xxxx-borders">8.8±6.4</td><td class="xxxx-borders">—</td><td class="xxxr-borders">—</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Intravenous regimen</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Evinacumab</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">15 mg/kg every 4 wk</td><td class="xxxx-borders shading">38</td><td class="xxxx-borders shading">–49.9±6.1</td><td class="xxxx-borders shading">–50.5±9.0 (–68.4 to –32.6)</td><td class="xxxr-borders shading">&lt;0.001</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">5 mg/kg every 4 wk</td><td class="xxxx-borders">35</td><td class="xxxx-borders">–23.5±6.6</td><td class="xxxx-borders">–24.2±9.3 (–42.6 to –5.7)<a href="#core-t3fn2" role="doc-noteref">†</a></td><td class="xxxr-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Placebo, every 4 wk</td><td class="xbxx-borders shading">33</td><td class="xbxx-borders shading">0.6±6.6</td><td class="xbxx-borders shading">—</td><td class="xbxr-borders shading">—</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">Plus–minus values are least-squares means ±SE. Data are shown for the intention-to-treat population.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t3fn2" role="paragraph" data-to-manipulate="true">The width of the 95% confidence interval has not been adjusted for multiplicity and cannot be used to infer treatment effects.</div></div></div></figcaption></a><figcaption><div class="caption">Change from Baseline in the Calculated LDL Cholesterol Level at Week 16 in Patients with Refractory Hypercholesterolemia.<a href="#core-t3fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2031049_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t4"><figure class="table"><a class="open-in-viewer" href="#t4" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2031049_t4.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2031049/asset/6cbe70fd-937f-4666-a090-dc6cfbaf1167/assets/images/large/nejmoa2031049_t4.jpg" height="1834" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Trial Group</th><th class="txxx-borders">No. of Patients</th><th class="txxx-borders">Any Adverse Event</th><th class="txxx-borders">≥1 Serious Adverse Event</th><th class="txxx-borders">≥1 Adverse Event Resulting in Treatment Discontinuation</th><th class="txxr-borders">Any Adverse Event Resulting in Death</th></tr><tr class="headc" data-type="row headc" data-xml-valign="top"><td class="xxlx-borders hanging02">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><th class="xxxr-borders" colspan="4"><span><i>number of patients (percent)</i></span></th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Subcutaneous regimen</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Evinacumab</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">450 mg weekly</td><td class="xxxx-borders shading">40</td><td class="xxxx-borders shading">27 (68)<a href="#core-t4fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">3 (8)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">300 mg weekly</td><td class="xxxx-borders">42</td><td class="xxxx-borders">28 (67)<a href="#core-t4fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">3 (7)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">300 mg every 2 wk</td><td class="xxxx-borders shading">39</td><td class="xxxx-borders shading">32 (82)<a href="#core-t4fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">2 (5)</td><td class="xxxx-borders shading">2 (5)</td><td class="xxxr-borders shading">1 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Placebo, weekly</td><td class="xxxx-borders">39</td><td class="xxxx-borders">21 (54)<a href="#core-t4fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">3 (8)</td><td class="xxxx-borders">2 (5)</td><td class="xxxr-borders">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Intravenous regimen</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Evinacumab</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">15 mg/kg every 4 wk</td><td class="xxxx-borders shading">37</td><td class="xxxx-borders shading">31 (84)<a href="#core-t4fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">6 (16)</td><td class="xxxx-borders shading">2 (5)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">5 mg/kg every 4 wk</td><td class="xxxx-borders">36</td><td class="xxxx-borders">27 (75)<a href="#core-t4fn7" role="doc-noteref">**</a></td><td class="xxxx-borders">2 (6)</td><td class="xxxx-borders">2 (6)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Placebo, every 4 wk</td><td class="xbxx-borders shading">33</td><td class="xbxx-borders shading">23 (70)<a href="#core-t4fn8" role="doc-noteref">††</a></td><td class="xbxx-borders shading">1 (3)</td><td class="xbxx-borders shading">1 (3)</td><td class="xbxr-borders shading">0</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t4fn1" role="paragraph" data-to-manipulate="true">Data are shown for the double-blind safety analysis population, which included 266 patients.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t4fn2" role="paragraph" data-to-manipulate="true">The most common adverse events that occurred with subcutaneous evinacumab at a dose of 450 mg weekly were diarrhea (8%), headache (10%), influenza-like illness (8%), injection-site erythema (10%), nausea (10%), nasopharyngitis (10%), and urinary tract infection (10%).</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t4fn3" role="paragraph" data-to-manipulate="true">The most common adverse events that occurred with subcutaneous evinacumab at a dose of 300 mg weekly were chest pain (7%), fall (7%), headache (7%), injection-site hemorrhage (7%), injection-site hematoma (7%), back pain (10%), nasopharyngitis (10%), oropharyngeal pain (10%), and urinary tract infection (10%).</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t4fn4" role="paragraph" data-to-manipulate="true">The most common adverse events that occurred with subcutaneous evinacumab at a dose of 300 mg every 2 weeks were arthralgia (8%), back pain (8%), myalgia (8%), constipation (10%), nausea (10%), nasopharyngitis (10%), and urinary tract infection (13%).</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t4fn5" role="paragraph" data-to-manipulate="true">The most common adverse events that occurred with subcutaneous placebo were diarrhea (8%), fatigue (8%), nausea (8%), urinary tract infection (8%), headache (10%), back pain (13%), dizziness (13%), and nasopharyngitis (15%).</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t4fn6" role="paragraph" data-to-manipulate="true">The most common adverse events that occurred with intravenous evinacumab at a dose of 15 mg per kilogram every 4 weeks were asthenia (8%), dizziness (8%), hypertension (14%), and nasopharyngitis (16%).</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="core-t4fn7" role="paragraph" data-to-manipulate="true">The most common adverse events that occurred with intravenous evinacumab at a dose of 5 mg per kilogram every 4 weeks were influenza-like illness (8%), pain in an arm or leg (8%), nasopharyngitis (8%), fatigue (11%), and myalgia (11%).</div></div><div role="doc-footnote" data-has="label"><div class="label">††</div><div id="core-t4fn8" role="paragraph" data-to-manipulate="true">The most common adverse events that occurred with intravenous placebo were arthralgia (9%), influenza-like illness (9%), myalgia (12%), and headache (18%).</div></div></div></figcaption></a><figcaption><div class="caption">Overall Safety Profile of Subcutaneous and Intravenous Evinacumab during the Double-Blind Treatment Period in Patients with Refractory Hypercholesterolemia.<a href="#core-t4fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t4"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t4" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2031049_t4.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2031049</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies: a consensus statement from the European Atherosclerosis Society Consensus Panel. <em>Eur Heart J</em> 2017;38:2459-2472.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/eurheartj/ehx144" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28444290/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000408001800012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Low-density+lipoproteins+cause+atherosclerotic+cardiovascular+disease.+1.+Evidence+from+genetic%2C+epidemiologic%2C+and+clinical+studies%3A+a+consensus+statement+from+the+European+Atherosclerosis+Society+Consensus+Panel.&amp;publication_year=2017&amp;journal=Eur+Heart+J&amp;pages=2459-2472&amp;doi=10.1093%2Feurheartj%2Fehx144&amp;pmid=28444290" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Khera AV, Won H-H, Peloso GM, et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. <em>J Am Coll Cardiol</em> 2016;67:2578-2589.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r2-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jacc.2016.03.520" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27050191/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000377271300003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Diagnostic+yield+and+clinical+utility+of+sequencing+familial+hypercholesterolemia+genes+in+patients+with+severe+hypercholesterolemia.&amp;publication_year=2016&amp;journal=J+Am+Coll+Cardiol&amp;pages=2578-2589&amp;doi=10.1016%2Fj.jacc.2016.03.520&amp;pmid=27050191" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r2-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r2-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] deciliter (4.91 mmol per liter) or higher. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r2-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] patients with severe hypercholesterolemia. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r2-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] to elevated LDL cholesterol levels. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects. <em>J Am Coll Cardiol</em> 2020;75:2553-2566.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jacc.2020.03.057" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32439005/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000536789100005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Worldwide+prevalence+of+familial+hypercholesterolemia%3A+meta-analyses+of+11+million+subjects.&amp;publication_year=2020&amp;journal=J+Am+Coll+Cardiol&amp;pages=2553-2566&amp;doi=10.1016%2Fj.jacc.2020.03.057&amp;pmid=32439005" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r3-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] with severe hypercholesterolemia was 7.2%. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r3-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] suggests that 1 in 313 people is affected. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r3-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] the prevalence in the general population. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Gidding SS, Champagne MA, de Ferranti SD, et al. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. <em>Circulation</em> 2015;132:2167-2192.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1161/CIR.0000000000000297" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26510694/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000366187100010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+agenda+for+familial+hypercholesterolemia%3A+a+scientific+statement+from+the+American+Heart+Association.&amp;publication_year=2015&amp;journal=Circulation&amp;pages=2167-2192&amp;doi=10.1161%2FCIR.0000000000000297&amp;pmid=26510694" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] an elevated plasma LDL cholesterol level. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] coverage support, and adverse events. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">McGowan MP, Hosseini Dehkordi SH, Moriarty PM, Duell PB. Diagnosis and treatment of heterozygous familial hypercholesterolemia. <em>J Am Heart Assoc</em> 2019;8(24):e013225-e013225.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1161/JAHA.119.013225" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31838973/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000514326200002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Diagnosis+and+treatment+of+heterozygous+familial+hypercholesterolemia.&amp;publication_year=2019&amp;journal=J+Am+Heart+Assoc&amp;pages=e013225-e013225&amp;doi=10.1161%2FJAHA.119.013225&amp;pmid=31838973" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. <em>Eur Heart J</em> 2013;34:3478-390a.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/eurheartj/eht273" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23956253/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000328393500009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Familial+hypercholesterolaemia+is+underdiagnosed+and+undertreated+in+the+general+population%3A+guidance+for+clinicians+to+prevent+coronary+heart+disease%3A+consensus+statement+of+the+European+Atherosclerosis+Society.&amp;publication_year=2013&amp;journal=Eur+Heart+J&amp;pages=3478-390a&amp;doi=10.1093%2Feurheartj%2Feht273&amp;pmid=23956253" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Gallo A, Charriere S, Vimont A, et al. SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia. <em>Atherosclerosis</em> 2020;306:41-49.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.atherosclerosis.2020.06.011" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32688103/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000568235700007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=SAFEHEART+risk-equation+and+cholesterol-year-score+are+powerful+predictors+of+cardiovascular+events+in+French+patients+with+familial+hypercholesterolemia.&amp;publication_year=2020&amp;journal=Atherosclerosis&amp;pages=41-49&amp;doi=10.1016%2Fj.atherosclerosis.2020.06.011&amp;pmid=32688103" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Khera AV, Chaffin M, Zekavat SM, et al. Whole-genome sequencing to characterize monogenic and polygenic contributions in patients hospitalized with early-onset myocardial infarction. <em>Circulation</em> 2019;139:1593-1602.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1161/CIRCULATIONAHA.118.035658" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30586733/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000469319000009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Whole-genome+sequencing+to+characterize+monogenic+and+polygenic+contributions+in+patients+hospitalized+with+early-onset+myocardial+infarction.&amp;publication_year=2019&amp;journal=Circulation&amp;pages=1593-1602&amp;doi=10.1161%2FCIRCULATIONAHA.118.035658&amp;pmid=30586733" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <em>Eur Heart J</em> 2020;41:111-188.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/eurheartj/ehz455" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31504418/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000605984300013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2019+ESC%2FEAS+guidelines+for+the+management+of+dyslipidaemias%3A+lipid+modification+to+reduce+cardiovascular+risk.&amp;publication_year=2020&amp;journal=Eur+Heart+J&amp;pages=111-188&amp;doi=10.1093%2Feurheartj%2Fehz455&amp;pmid=31504418" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] cardiovascular disease, respectively. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] a statin, ezetimibe, and a PCSK9 inhibitor. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] for atherosclerotic cardiovascular disease </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. <em>Circulation</em> 2019;139(25):e1082-e1143.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30586774/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000471794100005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2018+AHA%2FACC%2FAACVPR%2FAAPA%2FABC%2FACPM%2FADA%2FAGS%2FAPhA%2FASPC%2FNLA%2FPCNA+guideline+on+the+management+of+blood+cholesterol%3A+a+report+of+the+American+College+of+Cardiology%2FAmerican+Heart+Association+task+force+on+clinical+practice+guidelines.&amp;publication_year=2019&amp;journal=Circulation&amp;pages=e1082-e1143&amp;pmid=30586774" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] for atherosclerotic cardiovascular disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] for atherosclerotic cardiovascular disease. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Wang A, Richhariya A, Gandra SR, et al. Systematic review of low-density lipoprotein cholesterol apheresis for the treatment of familial hypercholesterolemia. <em>J Am Heart Assoc</em> 2016;5(7):e003294-e003294.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1161/JAHA.116.003294" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27385428/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000386713800022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Systematic+review+of+low-density+lipoprotein+cholesterol+apheresis+for+the+treatment+of+familial+hypercholesterolemia.&amp;publication_year=2016&amp;journal=J+Am+Heart+Assoc&amp;pages=e003294-e003294&amp;doi=10.1161%2FJAHA.116.003294&amp;pmid=27385428" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Ishigaki Y, Kawagishi N, Hasegawa Y, et al. Liver transplantation for homozygous familial hypercholesterolemia. <em>J Atheroscler Thromb</em> 2019;26:121-127.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.5551/jat.RV17029" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30555131/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000457404700003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Liver+transplantation+for+homozygous+familial+hypercholesterolemia.&amp;publication_year=2019&amp;journal=J+Atheroscler+Thromb&amp;pages=121-127&amp;doi=10.5551%2Fjat.RV17029&amp;pmid=30555131" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Tikka A, Jauhiainen M. The role of ANGPTL3 in controlling lipoprotein metabolism. <em>Endocrine</em> 2016;52:187-193.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s12020-015-0838-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26754661/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000373961700003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+role+of+ANGPTL3+in+controlling+lipoprotein+metabolism.&amp;publication_year=2016&amp;journal=Endocrine&amp;pages=187-193&amp;doi=10.1007%2Fs12020-015-0838-9&amp;pmid=26754661" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Kersten S. Angiopoietin-like 3 in lipoprotein metabolism. <em>Nat Rev Endocrinol</em> 2017;13:731-739.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nrendo.2017.119" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28984319/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000414767300017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Angiopoietin-like+3+in+lipoprotein+metabolism.&amp;publication_year=2017&amp;journal=Nat+Rev+Endocrinol&amp;pages=731-739&amp;doi=10.1038%2Fnrendo.2017.119&amp;pmid=28984319" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Musunuru K, Pirruccello JP, Do R, et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. <em>N Engl J Med</em> 2010;363:2220-2227.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r15-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_16_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2031049&amp;key=10.1056%2FNEJMoa1002926&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20942659/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000284832900009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Exome+sequencing%2C+ANGPTL3+mutations%2C+and+familial+combined+hypolipidemia.&amp;publication_year=2010&amp;journal=N+Engl+J+Med&amp;pages=2220-2227&amp;doi=10.1056%2FNEJMoa1002926&amp;pmid=20942659" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r15-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r17" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] lipoprotein lipase and endothelial lipase. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] which is a consequence of ANGPTL3 blockade. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Adam RC, Mintah IJ, Alexa-Braun CA, et al. Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance. <em>J Lipid Res</em> 2020;61:1271-1286.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32646941/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Angiopoietin-like+protein+3+governs+LDL-cholesterol+levels+through+endothelial+lipase-dependent+VLDL+clearance.&amp;publication_year=2020&amp;pages=1271-1286&amp;pmid=32646941" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Wu L, Soundarapandian MM, Castoreno AB, Millar JS, Rader DJ. LDL-cholesterol reduction by ANGPTL3 inhibition in mice is dependent on endothelial lipase. <em>Circ Res</em> 2020;127:1112-1114.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1161/CIRCRESAHA.120.317128" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32808882/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000576633500012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=LDL-cholesterol+reduction+by+ANGPTL3+inhibition+in+mice+is+dependent+on+endothelial+lipase.&amp;publication_year=2020&amp;journal=Circ+Res&amp;pages=1112-1114&amp;doi=10.1161%2FCIRCRESAHA.120.317128&amp;pmid=32808882" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Dewey FE, Gusarova V, Dunbar RL, et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. <em>N Engl J Med</em> 2017;377:211-221.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r18-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_19_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2031049&amp;key=10.1056%2FNEJMoa1612790&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28538136/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000405777600005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Genetic+and+pharmacologic+inactivation+of+ANGPTL3+and+cardiovascular+disease.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=211-221&amp;doi=10.1056%2FNEJMoa1612790&amp;pmid=28538136" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r18-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r18-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] high-density lipoprotein (HDL) cholesterol. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] than the risk in the general population. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] increased risk of cardiovascular disease. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Gaudet D, Gipe DA, Pordy R, et al. ANGPTL3 inhibition in homozygous familial hypercholesterolemia. <em>N Engl J Med</em> 2017;377:296-297.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r19-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_20_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2031049&amp;key=10.1056%2FNEJMc1705994&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28723334/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000405777600017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=ANGPTL3+inhibition+in+homozygous+familial+hypercholesterolemia.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=296-297&amp;doi=10.1056%2FNEJMc1705994&amp;pmid=28723334" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r19-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r21-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] mechanism independent of the LDL receptor. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] homozygous familial hypercholesterolemia, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Banerjee P, Chan K-C, Tarabocchia M, et al. Functional analysis of LDLR (low-density lipoprotein receptor) variants in patient lymphocytes to assess the effect of evinacumab in homozygous familial hypercholesterolemia patients with a spectrum of LDLR activity. <em>Arterioscler Thromb Vasc Biol</em> 2019;39:2248-2260.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1161/ATVBAHA.119.313051" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31578082/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000494483700013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Functional+analysis+of+LDLR+%28low-density+lipoprotein+receptor%29+variants+in+patient+lymphocytes+to+assess+the+effect+of+evinacumab+in+homozygous+familial+hypercholesterolemia+patients+with+a+spectrum+of+LDLR+activity.&amp;publication_year=2019&amp;journal=Arterioscler+Thromb+Vasc+Biol&amp;pages=2248-2260&amp;doi=10.1161%2FATVBAHA.119.313051&amp;pmid=31578082" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Gusarova V, Alexa CA, Wang Y, et al. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. <em>J Lipid Res</em> 2015;56:1308-1317.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r21-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1194/jlr.M054890" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25964512/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000356834700008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=ANGPTL3+blockade+with+a+human+monoclonal+antibody+reduces+plasma+lipids+in+dyslipidemic+mice+and+monkeys.&amp;publication_year=2015&amp;journal=J+Lipid+Res&amp;pages=1308-1317&amp;doi=10.1194%2Fjlr.M054890&amp;pmid=25964512" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r21-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r21-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] mechanism independent of the LDL receptor. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] which is a consequence of ANGPTL3 blockade. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for homozygous familial hypercholesterolemia. <em>N Engl J Med</em> 2020;383:711-720.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r22-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_23_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2031049&amp;key=10.1056%2FNEJMoa2004215&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32813947/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000563818700011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Evinacumab+for+homozygous+familial+hypercholesterolemia.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=711-720&amp;doi=10.1056%2FNEJMoa2004215&amp;pmid=32813947" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r22-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r22-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] (&lt;2% LDL receptor activity). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] compared with a 0.8% increase with placebo. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] in the pivotal phase 3 ELIPSE HoFH trial. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] homozygous familial hypercholesterolemia, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. <em>Clin Chem</em> 1972;18:499-502.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/clinchem/18.6.499" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/4337382/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1972M604800001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Estimation+of+the+concentration+of+low-density+lipoprotein+cholesterol+in+plasma%2C+without+use+of+the+preparative+ultracentrifuge.&amp;publication_year=1972&amp;journal=Clin+Chem&amp;pages=499-502&amp;doi=10.1093%2Fclinchem%2F18.6.499&amp;pmid=4337382" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">van Delden XM, Huijgen R, Wolmarans KH, et al. LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: minority at target despite large reductions in LDL-C. <em>Atherosclerosis</em> 2018;277:327-333.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.atherosclerosis.2018.06.820" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30270067/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000445908000050" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=LDL-cholesterol+target+achievement+in+patients+with+heterozygous+familial+hypercholesterolemia+at+Groote+Schuur+Hospital%3A+minority+at+target+despite+large+reductions+in+LDL-C.&amp;publication_year=2018&amp;journal=Atherosclerosis&amp;pages=327-333&amp;doi=10.1016%2Fj.atherosclerosis.2018.06.820&amp;pmid=30270067" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Rallidis LS, Liberopoulos EN, Vlachopoulos C, et al. Very high-risk familial hypercholesterolaemia patients in real life: the remaining gap in achieving the current LDL-C targets despite the use of PCSK9 inhibitors. <em>Atherosclerosis</em> 2020;309:67-69.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r25-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.atherosclerosis.2020.07.018" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32859385/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000573866600010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Very+high-risk+familial+hypercholesterolaemia+patients+in+real+life%3A+the+remaining+gap+in+achieving+the+current+LDL-C+targets+despite+the+use+of+PCSK9+inhibitors.&amp;publication_year=2020&amp;journal=Atherosclerosis&amp;pages=67-69&amp;doi=10.1016%2Fj.atherosclerosis.2020.07.018&amp;pmid=32859385" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r25-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r25-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] have a high baseline LDL cholesterol level. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r28" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] the optimization of treatment regimens. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r25-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] despite treatment with PCSK9 inhibitors. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r25-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] level of less than 55 mg per deciliter. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. <em>Eur Heart J</em> 2016;37:2999-3058.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/eurheartj/ehw272" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27567407/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000387990800012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2016+ESC%2FEAS+guidelines+for+the+management+of+dyslipidaemias.&amp;publication_year=2016&amp;journal=Eur+Heart+J&amp;pages=2999-3058&amp;doi=10.1093%2Feurheartj%2Fehw272&amp;pmid=27567407" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="core-r27" class="citations"><div class="citation"><div class="citation-content">Raal FJ, Hovingh GK, Catapano AL. Familial hypercholesterolemia treatments: guidelines and new therapies. <em>Atherosclerosis</em> 2018;277:483-492.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.atherosclerosis.2018.06.859" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30270089/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000445908000072" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Familial+hypercholesterolemia+treatments%3A+guidelines+and+new+therapies.&amp;publication_year=2018&amp;journal=Atherosclerosis&amp;pages=483-492&amp;doi=10.1016%2Fj.atherosclerosis.2018.06.859&amp;pmid=30270089" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="core-r28" class="citations"><div class="citation"><div class="citation-content">Rosenson RS, Baker S, Banach M, et al. Optimizing cholesterol treatment in patients with muscle complaints. <em>J Am Coll Cardiol</em> 2017;70:1290-1301.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jacc.2017.07.752" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28859793/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000408453600012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Optimizing+cholesterol+treatment+in+patients+with+muscle+complaints.&amp;publication_year=2017&amp;journal=J+Am+Coll+Cardiol&amp;pages=1290-1301&amp;doi=10.1016%2Fj.jacc.2017.07.752&amp;pmid=28859793" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="core-r29" class="citations"><div class="citation"><div class="citation-content">Catapano AL, Lee LV, Louie MJ, Thompson D, Bergeron J, Krempf M. Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trials. <em>Sci Rep</em> 2017;7:45788-45788.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/srep45788" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28374849/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000398149800001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+of+alirocumab+according+to+background+statin+type+and+dose%3A+pooled+analysis+of+8+ODYSSEY+Phase+3+clinical+trials.&amp;publication_year=2017&amp;journal=Sci+Rep&amp;pages=45788-45788&amp;doi=10.1038%2Fsrep45788&amp;pmid=28374849" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="core-r30" class="citations"><div class="citation"><div class="citation-content">Rosenson RS, Hegele RA, Koenig W. Cholesterol-lowering agents. <em>Circ Res</em> 2019;124:364-385.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1161/CIRCRESAHA.118.313238" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30702994/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000457466300002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Cholesterol-lowering+agents.&amp;publication_year=2019&amp;journal=Circ+Res&amp;pages=364-385&amp;doi=10.1161%2FCIRCRESAHA.118.313238&amp;pmid=30702994" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="core-r31" class="citations"><div class="citation"><div class="citation-content">Guedeney P, Giustino G, Sorrentino S, et al. Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. <em>Eur Heart J</em> 2019 July 3 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/eurheartj/ehz746.0332" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31270529/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000507313002927" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+alirocumab+and+evolocumab%3A+a+systematic+review+and+meta-analysis+of+randomized+controlled+trials.&amp;publication_year=2019&amp;journal=Eur+Heart+J&amp;doi=10.1093%2Feurheartj%2Fehz746.0332&amp;pmid=31270529" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="core-r32" class="citations"><div class="citation"><div class="citation-content">Reeskamp LF, Tromp TR, Stroes ESG. The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease? <em>Curr Opin Lipidol</em> 2020;31:140-146.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r33"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/MOL.0000000000000679" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32324598/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000561384000005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+next+generation+of+triglyceride-lowering+drugs%3A+will+reducing+apolipoprotein+C-III+or+angiopoietin+like+protein+3+reduce+cardiovascular+disease%3F&amp;publication_year=2020&amp;journal=Curr+Opin+Lipidol&amp;pages=140-146&amp;doi=10.1097%2FMOL.0000000000000679&amp;pmid=32324598" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="core-r33" class="citations"><div class="citation"><div class="citation-content">Lincoff AM, Nicholls SJ, Riesmeyer JS, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. <em>N Engl J Med</em> 2017;376:1933-1942.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r33"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_34_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2031049&amp;key=10.1056%2FNEJMoa1609581&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28514624/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000401407500007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Evacetrapib+and+cardiovascular+outcomes+in+high-risk+vascular+disease.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=1933-1942&amp;doi=10.1056%2FNEJMoa1609581&amp;pmid=28514624" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="core-r34" class="citations"><div class="citation"><div class="citation-content">Ference BA, Kastelein JJP, Ray KK, et al. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. <em>JAMA</em> 2019;321:364-373.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r34"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2018.20045" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30694319/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000457130400022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Association+of+triglyceride-lowering+LPL+variants+and+LDL-C-lowering+LDLR+variants+with+risk+of+coronary+heart+disease.&amp;publication_year=2019&amp;journal=JAMA&amp;pages=364-373&amp;doi=10.1001%2Fjama.2018.20045&amp;pmid=30694319" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="core-r35" class="citations"><div class="citation"><div class="citation-content">Toth PP, Granowitz C, Hull M, Liassou D, Anderson A, Philip S. High triglycerides are associated with increased cardiovascular events, medical costs, and resource use: a real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk. <em>J Am Heart Assoc</em> 2018;7(15):e008740-e008740.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1161/JAHA.118.008740" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30371242/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000452701900009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=High+triglycerides+are+associated+with+increased+cardiovascular+events%2C+medical+costs%2C+and+resource+use%3A+a+real-world+administrative+claims+analysis+of+statin-treated+patients+with+high+residual+cardiovascular+risk.&amp;publication_year=2018&amp;journal=J+Am+Heart+Assoc&amp;pages=e008740-e008740&amp;doi=10.1161%2FJAHA.118.008740&amp;pmid=30371242" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">36.</div><div id="core-r36" class="citations"><div class="citation"><div class="citation-content">Tavori H, Giunzioni I, Fazio S. PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9. <em>Curr Opin Endocrinol Diabetes Obes</em> 2015;22:126-132.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r36"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/MED.0000000000000137" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25692926/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=PCSK9+inhibition+to+reduce+cardiovascular+disease+risk%3A+recent+findings+from+the+biology+of+PCSK9.&amp;publication_year=2015&amp;journal=Curr+Opin+Endocrinol+Diabetes+Obes&amp;pages=126-132&amp;doi=10.1097%2FMED.0000000000000137&amp;pmid=25692926" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">37.</div><div id="core-r37" class="citations"><div class="citation"><div class="citation-content">Bittner B, Richter W, Schmidt J. Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. <em>BioDrugs</em> 2018;32:425-440.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r37-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s40259-018-0295-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30043229/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000446665700004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Subcutaneous+administration+of+biotherapeutics%3A+an+overview+of+current+challenges+and+opportunities.&amp;publication_year=2018&amp;journal=BioDrugs&amp;pages=425-440&amp;doi=10.1007%2Fs40259-018-0295-0&amp;pmid=30043229" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r37-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r38" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] of work productivity and personal time. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r37-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] health care costs related to drug delivery. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">38.</div><div id="core-r38" class="citations"><div class="citation"><div class="citation-content">Johnson ML, Braiteh F, Grilley-Olson JE, et al. Assessment of subcutaneous vs intravenous administration of anti-PD-1 antibody PF-06801591 in patients with advanced solid tumors: a phase 1 dose-escalation trial. <em>JAMA Oncol</em> 2019;5:999-1007.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r38"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jamaoncol.2019.0836" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31145415/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000481511600016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Assessment+of+subcutaneous+vs+intravenous+administration+of+anti-PD-1+antibody+PF-06801591+in+patients+with+advanced+solid+tumors%3A+a+phase+1+dose-escalation+trial.&amp;publication_year=2019&amp;journal=JAMA+Oncol&amp;pages=999-1007&amp;doi=10.1001%2Fjamaoncol.2019.0836&amp;pmid=31145415" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">39.</div><div id="core-r39" class="citations"><div class="citation"><div class="citation-content">Ginsberg HN, Rader DJ, Raal FJ, et al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg/dl or higher. <em>Cardiovasc Drugs Ther</em> 2016;30:473-483.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r40"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s10557-016-6685-y" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27618825/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000385185600006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+alirocumab+in+patients+with+heterozygous+familial+hypercholesterolemia+and+LDL-C+of+160+mg%2Fdl+or+higher.&amp;publication_year=2016&amp;journal=Cardiovasc+Drugs+Ther&amp;pages=473-483&amp;doi=10.1007%2Fs10557-016-6685-y&amp;pmid=27618825" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">40.</div><div id="core-r40" class="citations"><div class="citation"><div class="citation-content">Santos RD, Stein EA, Hovingh GK, et al. Long-term evolocumab in patients with familial hypercholesterolemia. <em>J Am Coll Cardiol</em> 2020;75:565-574.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r40"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jacc.2019.12.020" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32057369/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000512903000001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Long-term+evolocumab+in+patients+with+familial+hypercholesterolemia.&amp;publication_year=2020&amp;journal=J+Am+Coll+Cardiol&amp;pages=565-574&amp;doi=10.1016%2Fj.jacc.2019.12.020&amp;pmid=32057369" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/editorial" class="issue-item_type">Editorial</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Dec 09, 2020</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMe2032798" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Factoring in ANGPTL3 When LDL Is Refractory</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">S.S. Martin</span></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 9, 2025</div><div class="nejm-widget_item"><div><span> Freehold, New Jersey</span></div><div><span>Hematology / Oncology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/886964/hematologist-oncologist-regional-cancer-care-associates-freehold/?query=fjwp&amp;rid=5696">Hematologist/Oncologist - Regional Cancer Care Associates Freehold</a></div></div><div class="nejm-widget_item"><div><span> Massachusetts</span></div><div><span>Obstetrics &amp; Gynecology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/876188/ob-gyn-physician/?query=fjwp&amp;rid=165114">OB/GYN Physician</a></div></div><div class="nejm-widget_item"><div><span> Pittsfield, Massachusetts</span></div><div><span>Cardiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/886908/non-invasive-cardiologist-opportunity-with-a-concentration-on-advanced-imaging-western-ma-/?query=fjwp&amp;rid=886">Non-Invasive Cardiologist Opportunity with a Concentration on Advanced Imaging! Western, MA!</a></div></div><div class="nejm-widget_item"><div><span> Cherry Hill, New Jersey</span></div><div><span>Urology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/889507/urologist-full-time-jefferson-health-southern-new-jersey/?query=fjwf&amp;rid=271428">Urologist - Full Time - Jefferson Health - Southern New Jersey</a></div></div><div class="nejm-widget_item"><div><span> Pittsfield, Massachusetts</span></div><div><span>Cardiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/865638/progressive-patient-centric-noninvasive-cardiologist-opportunity-in-beautiful-western-mass-/?query=fjwp&amp;rid=886">Progressive, Patient-Centric, Noninvasive Cardiologist Opportunity in Beautiful Western Mass!</a></div></div><div class="nejm-widget_item"><div><span> Fullerton, California</span></div><div><span>Gastroenterology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/883874/gastroenterologist/?query=fjwf&amp;rid=329661">Gastroenterologist</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128129&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Falerts%3Fpromo%3DONFQSR51%26query%3Dcm_rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dalerts23&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2031049&amp;pubId=41289025&amp;placeholderId=101337&amp;productId=1035"><img src="/sda/128129/rightRail--SpecialtyUpdates23-001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d65b3a97347810-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d65b3a97347810-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d65b3a97347810-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$237786631$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$237786631$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$237786631$--></div></div><div class="mlt-body"><!--?lit$237786631$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$237786631$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$237786631$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$237786631$-->Aug 20, 2020</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2004215?query=recirc_Semantic" target="_self">Evinacumab for Homozygous Familial Hypercholesterolemia</a></div><div class="mlt-article-authors"><!--?lit$237786631$-->F.J. Raal and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/correspondence" target="_self"><!--?lit$237786631$-->Correspondence</a> <span class="mlt-article-site-label"><!--?lit$237786631$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$237786631$-->Feb 11, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMc2033612?query=recirc_Semantic" target="_self">Evinacumab for Homozygous Familial Hypercholesterolemia</a></div><div class="mlt-article-authors"><!--?lit$237786631$--></div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/editorial" target="_self"><!--?lit$237786631$-->Editorial</a> <span class="mlt-article-site-label"><!--?lit$237786631$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$237786631$-->Aug 20, 2020</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMe2023520?query=recirc_Semantic" target="_self">Bypassing the LDL Receptor in Familial Hypercholesterolemia</a></div><div class="mlt-article-authors"><!--?lit$237786631$-->S. Kersten</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$237786631$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$237786631$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$237786631$-->Aug 24, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2304146?query=recirc_Semantic" target="_self">Pitavastatin to Prevent Cardiovascular Disease in HIV Infection</a></div><div class="mlt-article-authors"><!--?lit$237786631$-->S.K. Grinspoon and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$237786631$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$237786631$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$237786631$-->Nov 17, 2022</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2211023?query=recirc_Semantic" target="_self">Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease</a></div><div class="mlt-article-authors"><!--?lit$237786631$-->M.L. O’Donoghue and Others</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2031049?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2031049" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2031049.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2031049"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Evinacumab in Patients with Refractory Hypercholesterolemia</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMp2031055" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Withdrawing Approval of Makena — A Proposal from the FDA Center for Drug Evaluation and Research</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa2026920" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2031049_f1.jpg"><img src="/cms/10.1056/NEJMoa2031049/asset/5c7f9b97-f91e-40c3-bff7-98a3125bf75e/assets/images/large/nejmoa2031049_f1.jpg" height="1394" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Least-Squares Mean Percent Change from Baseline in the Calculated Low-Density Lipoprotein Cholesterol Level at Week 16.</div><div class="notes"><div role="doc-footnote">The least-squares mean and standard errors are taken from a mixed-effect model with a repeated-measures approach, with the categorical fixed effects of treatment (evinacumab or placebo), randomization strata (receipt of a high-intensity statin [yes or no] and presence of heterozygous familial hypercholesterolemia [yes or no]), time point up to week 16, treatment-by-time point interaction, and strata-by-time point interaction, as well as continuous fixed covariates of the calculated low-density lipoprotein (LDL) cholesterol level at baseline and baseline LDL cholesterol level-by-time point interaction. 𝙸 bars indicate standard errors.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients in the Subcutaneous-Treatment Groups.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Demographics and Clinical Characteristics of the Patients in the Intravenous-Treatment Groups.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Change from Baseline in the Calculated LDL Cholesterol Level at Week 16 in Patients with Refractory Hypercholesterolemia.<a href="#fv-t3fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t4" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 4</div><div class="fv__item__description"><figcaption><div class="caption">Overall Safety Profile of Subcutaneous and Intravenous Evinacumab during the Double-Blind Treatment Period in Patients with Refractory Hypercholesterolemia.<a href="#fv-t4fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/383/24" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 383 No. 24</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Dec 10, 2020</span></li><li data-toggle="tooltip" data-original-title="Visual Abstract" class="issue-item_meta-item"><span role="img" aria-label="Visual Abstract" tabindex="0" class="issue-item_visualAbstract"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-visual"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2028836" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Efficacy of Tocilizumab in Patients Hospitalized with Covid-19</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">J.H. Stone and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Dec 10, 2020</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2022485" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">M. Hussain and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Dec 10, 2020</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2026920" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">C. Keech and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2031049%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2031049&amp;pubId=41289025&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2031049%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2031049&amp;pubId=41289025&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id04307428141065699" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d65b3a97347810-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d65b3a97347810-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d65b3a97347810-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d65b3a97347810-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d65b3a97347810-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d65b3a97347810-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d65b3a97347810-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d65b3a97347810-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d65b3a97347810-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d65b3a97347810-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d65b3a88447810',t:'MTc0OTUzMjE2NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d65b3a88447810&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><vyu-rhiguvbtryfa></vyu-rhiguvbtryfa><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2031049?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=2-10"></script><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_mk0cqdodfa6cas1bawlgoe9efrjwllx29e18i312" data-transactionid="mk0cqdodfa6cas1bawlgoe9efrjwllx29e18i312" id="captureIFrame_mk0cqdodfa6cas1bawlgoe9efrjwllx29e18i312" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="mk0cqdodfa6cas1bawlgoe9efrjwllx29e18i312" target="captureIFrame_mk0cqdodfa6cas1bawlgoe9efrjwllx29e18i312" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_mk0cqdodfa6cas1bawlgoe9efrjwllx29e18i312" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_mk0cqdodfa6cas1bawlgoe9efrjwllx29e18i312" name="capture_screen"><input id="capture_signIn_js_version_mk0cqdodfa6cas1bawlgoe9efrjwllx29e18i312" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_mk0cqdodfa6cas1bawlgoe9efrjwllx29e18i312" name="js_version"><input id="capture_signIn_transactionId_mk0cqdodfa6cas1bawlgoe9efrjwllx29e18i312" data-capturefield="undefined" value="mk0cqdodfa6cas1bawlgoe9efrjwllx29e18i312" type="hidden" class="capture_transactionId_mk0cqdodfa6cas1bawlgoe9efrjwllx29e18i312" name="capture_transactionId"><input id="capture_signIn_form_mk0cqdodfa6cas1bawlgoe9efrjwllx29e18i312" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_mk0cqdodfa6cas1bawlgoe9efrjwllx29e18i312" name="form"><input id="capture_signIn_flow_mk0cqdodfa6cas1bawlgoe9efrjwllx29e18i312" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_mk0cqdodfa6cas1bawlgoe9efrjwllx29e18i312" name="flow"><input id="capture_signIn_client_id_mk0cqdodfa6cas1bawlgoe9efrjwllx29e18i312" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_mk0cqdodfa6cas1bawlgoe9efrjwllx29e18i312" name="client_id"><input id="capture_signIn_redirect_uri_mk0cqdodfa6cas1bawlgoe9efrjwllx29e18i312" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_mk0cqdodfa6cas1bawlgoe9efrjwllx29e18i312" name="redirect_uri"><input id="capture_signIn_response_type_mk0cqdodfa6cas1bawlgoe9efrjwllx29e18i312" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_mk0cqdodfa6cas1bawlgoe9efrjwllx29e18i312" name="response_type"><input id="capture_signIn_flow_version_mk0cqdodfa6cas1bawlgoe9efrjwllx29e18i312" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_mk0cqdodfa6cas1bawlgoe9efrjwllx29e18i312" name="flow_version"><input id="capture_signIn_settings_version_mk0cqdodfa6cas1bawlgoe9efrjwllx29e18i312" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_mk0cqdodfa6cas1bawlgoe9efrjwllx29e18i312" name="settings_version"><input id="capture_signIn_locale_mk0cqdodfa6cas1bawlgoe9efrjwllx29e18i312" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_mk0cqdodfa6cas1bawlgoe9efrjwllx29e18i312" name="locale"><input id="capture_signIn_recaptcha_version_mk0cqdodfa6cas1bawlgoe9efrjwllx29e18i312" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_mk0cqdodfa6cas1bawlgoe9efrjwllx29e18i312" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>